[{"title01":"Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome","title02":"Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 29. doi: 10.1111\/bjh.18424. Online ahead of print.","author":"van Leeuwen-Kerkhoff N, de Witte MA, Heijstek MW, Leavis HL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36039520"},{"title01":"MDM2 inhibition augments GVL effect","title02":"MDM2 inhibition augments GVL effect","journal":"Blood","issue":"2022 Sep 8;140(10):1064-1065.","author":"Bleakley M, Biernacki M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36074535"},{"title01":"Trafficking between clonally related peripheral T helper cells and tissue-resident T helper cells in chronic GVHD","title02":"Trafficking between clonally related peripheral T helper cells and tissue-resident T helper cells in chronic GVHD","journal":"Blood","issue":"Blood. 2022 Sep 9:blood.2022016581. doi: 10.1182\/blood.2022016581. Online ahead of print.","author":"Kong X, Wu X, Wang B, Zeng D, Cassady K, Nasri U, Zheng M, Wu A, Qin H, Tsai W, Salhotra A, Nakamura R, Martin PJ, Zeng D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36084473"},{"title01":"Effective treatment of low risk acute GVHD with itacitinib monotherapy","title02":"Effective treatment of low risk acute GVHD with itacitinib monotherapy","journal":"Blood","issue":"Blood. 2022 Sep 12:blood.2022017442. doi: 10.1182\/blood.2022017442. Online ahead of print.","author":"Etra AM, Capellini A, Alousi AM, Al Malki MM, Choe HK, DeFilipp Z, Hogan WJ, Kitko CL, Ayuk FA, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, \u00d6zbek U, Qayed M, Reshef R, Roesler W, Spyrou N, Young R, Chen YB, Ferrara JL, Levine JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36095841"},{"title01":"To transplant or not to transplant: that is the question in PTCL","title02":"To transplant or not to transplant: that is the question in PTCL","journal":"Blood","issue":"2022 Sep 1;140(9):936-937.","author":"Vose JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36048475"},{"title01":"Normalization of cerebral hemodynamics following hematopoietic stem cell transplant in children with sickle cell disease","title02":"Normalization of cerebral hemodynamics following hematopoietic stem cell transplant in children with sickle cell disease","journal":"Blood","issue":"Blood. 2022 Aug 30:blood.2022016618. doi: 10.1182\/blood.2022016618. Online ahead of print.","author":"Hulbert ML, Fields ME, Guilliams KP, Bijlani P, Shenoy S, Fellah S, Towerman AS, Binkley MM, McKinstry RC, Shimony JS, Chen Y, Eldeniz C, Ragan DK, Vo KD, An H, Lee JM, Ford AL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36040484"},{"title01":"A UNIQUE IMMUNE SIGNATURE IN BLOOD SEPARATES THERAPY-REFRACTORY FROM THERAPY-RESPONSIVE ACUTE GRAFT-VERSUS-HOST DISEASE","title02":"A UNIQUE IMMUNE SIGNATURE IN BLOOD SEPARATES THERAPY-REFRACTORY FROM THERAPY-RESPONSIVE ACUTE GRAFT-VERSUS-HOST DISEASE","journal":"Blood","issue":"Blood. 2022 Aug 31:blood.2022015734. doi: 10.1182\/blood.2022015734. Online ahead of print.","author":"van Halteren AGS, Suwandi J, Tuit S, Borst J, Laban S, Tsonaka R, Struijk A, Wiekmeijer AS, van Pel M, Roep BO, Zwaginga JJ, Lankester AC, Schepers K, van Tol MJD, Fibbe WE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36044666"},{"title01":"Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","title02":"Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","journal":"Blood","issue":"Blood. 2022 Aug 31:blood.2022016052. doi: 10.1182\/blood.2022016052. Online ahead of print.","author":"Mo F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, Brenner MK, Tkachev V, Mamonkin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36044667"},{"title01":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia","title02":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia","journal":"N Engl J Med","issue":"2022 Sep 1;387(9):859.","author":"Merli P, Guzzo I, Locatelli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36053525"},{"title01":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia. Reply","title02":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia. Reply","journal":"N Engl J Med","issue":"2022 Sep 1;387(9):860.","author":"Bertaina A, Grimm PC, Weinberg K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36053526"},{"title01":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial","title02":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial","journal":"Leukemia","issue":"Leukemia. 2022 Sep 12. doi: 10.1038\/s41375-022-01693-z. Online ahead of print.","author":"Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, Burkhardt B, Classen CF, Claviez A, Corbacioglu S, Deubzer HE, Greil J, Gruhn B, G\u00fcng\u00f6r T, Kafa K, K\u00fchl JS, Lang P, Lange BS, Meisel R, M\u00fcller I, Sauer MG, Schlegel PG, Schulz A, Stachel D, Strahm B, Wawer A, Peters C, Albert MH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36097283"},{"title01":"Alpha-beta T and B-cell depleted HLA-haploidentical HSCT in children with myelodysplastic syndromes","title02":"Alpha-beta T and B-cell depleted HLA-haploidentical HSCT in children with myelodysplastic syndromes","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.280698. Online ahead of print.","author":"Merli P, Pagliara D, Mina T, Bertaina V, Li Pira G, Lazzaro S, Biagini S, Galaverna F, Strocchio L, Carta R, Catanoso ML, Quagliarella F, Becilli M, Boccieri E, Del Bufalo F, Panigari A, Agostini A, Pedace L, Pizzi S, Perotti C, Algeri M, Zecca M, Locatelli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005558"},{"title01":"Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant","title02":"Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Sep 6. doi: 10.1111\/bjh.18441. Online ahead of print.","author":"Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36068929"},{"title01":"Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome","title02":"Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 29. doi: 10.1111\/bjh.18424. Online ahead of print.","author":"van Leeuwen-Kerkhoff N, de Witte MA, Heijstek MW, Leavis HL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36039520"},{"title01":"HSCs: slow me down with PLAG1","title02":"HSCs: slow me down with PLAG1","journal":"Blood","issue":"2022 Sep 1;140(9):935-936.","author":"Zhang YW, Cabezas-Wallscheid N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36048477"},{"title01":"Normalization of cerebral hemodynamics following hematopoietic stem cell transplant in children with sickle cell disease","title02":"Normalization of cerebral hemodynamics following hematopoietic stem cell transplant in children with sickle cell disease","journal":"Blood","issue":"Blood. 2022 Aug 30:blood.2022016618. doi: 10.1182\/blood.2022016618. Online ahead of print.","author":"Hulbert ML, Fields ME, Guilliams KP, Bijlani P, Shenoy S, Fellah S, Towerman AS, Binkley MM, McKinstry RC, Shimony JS, Chen Y, Eldeniz C, Ragan DK, Vo KD, An H, Lee JM, Ford AL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36040484"},{"title01":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","title02":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","journal":"Blood","issue":"Blood. 2022 Aug 31:blood.2022017960. doi: 10.1182\/blood.2022017960. Online ahead of print.","author":"Lawal RA, Mukherjee D, Limerick EM, Coles W, Hsieh MM, Dillon LW, Hourigan CS, Fitzhugh CD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36044658"},{"title01":"Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","title02":"Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","journal":"Blood","issue":"Blood. 2022 Aug 31:blood.2022016052. doi: 10.1182\/blood.2022016052. Online ahead of print.","author":"Mo F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, Brenner MK, Tkachev V, Mamonkin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36044667"},{"title01":"Luspatercept for the treatment of anaemia in non-transfusion-dependent \u03b2-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial","title02":"Luspatercept for the treatment of anaemia in non-transfusion-dependent \u03b2-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Aug 22:S2352-3026(22)00208-3. doi: 10.1016\/S2352-3026(22)00208-3. Online ahead of print.","author":"Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36007538"},{"title01":"Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria","title02":"Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Sep 2:JCO2200710. doi: 10.1200\/JCO.22.00710. Online ahead of print.","author":"Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L, Sebert M, Allain V, Patel BJ, Durmaz A, Pinto AL, Inacio MCB, Hernandez L, Dhedin N, Caillat-Zucman S, Clappier E, Sicre de Fontbrune F, Voso MT, Visconte V, Peffault de Latour R, Soulier J, Calado RT, Soci\u00e9 G, Maciejewski JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36054881"},{"title01":"Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine","title02":"Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine","journal":"N Engl J Med","issue":"N Engl J Med. 2022 Sep 14. doi: 10.1056\/NEJMc2210813. Online ahead of print.","author":"Herrera-Comoglio R, Lane S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36103622"},{"title01":"Humoral response to mRNA-based COVID-19 vaccine in patients with de novo and pre-existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination","title02":"Humoral response to mRNA-based COVID-19 vaccine in patients with de novo and pre-existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Sep 12. doi: 10.1111\/bjh.18447. Online ahead of print.","author":"Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36096497"},{"title01":"Immune thrombocytopenia and pregnancy: an exposed\/non-exposed cohort study","title02":"Immune thrombocytopenia and pregnancy: an exposed\/non-exposed cohort study","journal":"Blood","issue":"Blood. 2022 Sep 2:blood.2022017277. doi: 10.1182\/blood.2022017277. Online ahead of print.","author":"Guillet S, Loustau V, Boutin E, Zarour A, Comont T, Souchaud-Debouverie O, Costedoat N, Pan-Petesch B, Gobert D, Cheze S, Viallard JF, Morin AS, Sauvetre G, Cliquennois M, Royer B, Masseau A, Terriou L, Fieschi C, Lambotte O, Girault S, Lioger B, Audia S, Sacre K, Lega JC, Langlois V, Benachi A, Orvain C, Devidas A, Humbert S, Gambier N, Ruivard M, Zarrouk V, Ebbo M, Willems L, Segaux L, Mahevas M, Haddad B, Michel M, Canoui-Poitrine F, Godeau B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36054922"},{"title01":"Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Mild Thrombocytopenia","title02":"Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Mild Thrombocytopenia","journal":"Blood","issue":"Blood. 2022 Aug 26:blood.2022016757. doi: 10.1182\/blood.2022016757. Online ahead of print.","author":"Ayad NE, Grace RF, Kuter DJ, Al-Samkari H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36026607"},{"title01":"Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia","title02":"Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia","journal":"Blood","issue":"Blood. 2022 Aug 29:blood.2022016029. doi: 10.1182\/blood.2022016029. Online ahead of print.","author":"Ni X, Wang L, Wang H, Yu T, Xie J, Li G, Liu Y, Zhou H, Xu M, Hou M, Peng J, Hou Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36037415"},{"title01":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","title02":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.281233. Online ahead of print.","author":"Nilsson C, Linde F, Huleg\u00e5rdh E, Garelius H, Lazarevic V, Antunovic P, Cammenga J, Deneberg S, Eriksson A, J\u00e4dersten M, Bj\u00f6rkvall CK, M\u00f6llg\u00e5rd L, Wennstr\u00f6m L, \u00d6lander E, H\u00f6glund M, Juliusson G, Lehmann S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005563"},{"title01":"Lessons learned from therapy-related acute myeloid leukemia","title02":"Lessons learned from therapy-related acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.281742. Online ahead of print.","author":"Kayser S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005564"},{"title01":"HOXA9\/MEIS1 targets in leukemia: reinforced signaling networks and therapeutic opportunities","title02":"HOXA9\/MEIS1 targets in leukemia: reinforced signaling networks and therapeutic opportunities","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.281779. Online ahead of print.","author":"Zhou X, Lu R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005566"},{"title01":"Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study","title02":"Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Sep 9. doi: 10.1111\/bjh.18448. Online ahead of print.","author":"Kristensen DT, Nielsen LB, Jakobsen LHK, Kristensen TC, Jepsen L\u00d8, Sch\u00f6llkopf C, Theilgaard-M\u00f6nch K, El-Galaly TC, Roug AS, Severinsen MT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36083781"},{"title01":"Acute myeloid leukaemia presenting with Sweet syndrome","title02":"Acute myeloid leukaemia presenting with Sweet syndrome","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Sep 2. doi: 10.1111\/bjh.18439. Online ahead of print.","author":"Atkins O, Mirvis E, Maynard S, Katsomitrou V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36052836"},{"title01":"Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers","title02":"Rare germline ATM<\/i> variants of uncertain significance in chronic lymphocytic leukaemia and other cancers","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 26. doi: 10.1111\/bjh.18419. Online ahead of print.","author":"Petrackova A, Savara J, Turcsanyi P, Gajdos P, Papajik T, Kriegova E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36029002"},{"title01":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","title02":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 27. doi: 10.1111\/bjh.18418. Online ahead of print.","author":"Nakhoda S, Vistarop A, Wang YL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36029036"},{"title01":"Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia","title02":"Mutual exclusivity between the fusion gene CBFB::MYH11<\/i> and somatic mitochondrial mutations in acute myeloid leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 29. doi: 10.1111\/bjh.18444. Online ahead of print.","author":"Zhao C, Wang S, Wang K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36039018"},{"title01":"Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo","title02":"Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo","journal":"Blood","issue":"Blood. 2022 Sep 9:blood.2022016272. doi: 10.1182\/blood.2022016272. Online ahead of print.","author":"Martines C, Chakraborty S, Vujovikj M, Gobessi S, Vaisitti T, Deaglio S, Laurenti L, Dimovski AJ, Efremov DG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36084319"},{"title01":"Detecting measurable residual disease beyond 10-4 through an IGHV leader-based NGS approach improves prognostic stratification in CLL","title02":"Detecting measurable residual disease beyond 10-4 through an IGHV leader-based NGS approach improves prognostic stratification in CLL","journal":"Blood","issue":"Blood. 2022 Sep 9:blood.2022017411. doi: 10.1182\/blood.2022017411. Online ahead of print.","author":"Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, Robrecht S, Assmann JL, Van Der Straten L, Ritgen M, Westerweel PE, Fischer K, Goede V, Hallek M, Levin MD, Langerak AW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36084320"},{"title01":"The end of the beginning: Application of single cell sequencing to chronic lymphocytic leukemia (CLL)","title02":"The end of the beginning: Application of single cell sequencing to chronic lymphocytic leukemia (CLL)","journal":"Blood","issue":"Blood. 2022 Sep 12:blood.2021014669. doi: 10.1182\/blood.2021014669. Online ahead of print.","author":"Nagler A, Wu CJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36095842"},{"title01":"T\u03b3\u03b4 LGL LEUKEMIA IDENTIFIES A SUBSET WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF AN INTERNATIONAL COHORT OF 137 PATIENTS","title02":"T\u03b3\u03b4 LGL LEUKEMIA IDENTIFIES A SUBSET WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF AN INTERNATIONAL COHORT OF 137 PATIENTS","journal":"Blood","issue":"Blood. 2022 Sep 12:blood.2021013489. doi: 10.1182\/blood.2021013489. Online ahead of print.","author":"Barila' G, Grassi A, Cheon H, Teramo A, Calabretto G, Chahal JS, Vicenzetto C, Almeida J, Shemo BC, Shi M, Gasparini VRR, Munoz-Garcia N, Pastoret C, Nakazawa H, Oshimi K, Sokol L, Ishida F, Lamy T, Orfao A, Morice WG, Loughran T, Semenzato G, Zambello R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36096473"},{"title01":"uMRD: “the” endpoint or “an” endpoint for CLL?","title02":"uMRD: “the” endpoint or “an” endpoint for CLL?","journal":"Blood","issue":"2022 Aug 25;140(8):797-798.","author":"Kittai AS, Woyach JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36006672"},{"title01":"Chronic Conditions, Late Mortality and Health Status After Childhood AML: A Childhood Cancer Survivor Study Report","title02":"Chronic Conditions, Late Mortality and Health Status After Childhood AML: A Childhood Cancer Survivor Study Report","journal":"Blood","issue":"Blood. 2022 Aug 29:blood.2022016487. doi: 10.1182\/blood.2022016487. Online ahead of print.","author":"Turcotte LM, Whitton JA, Leisenring WM, Howell R, Neglia JP, Phelan R, Oeffinger KC, Ness KK, Woods WG, Kolb EA, Robison LL, Armstrong GT, Chow EJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36037430"},{"title01":"Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","title02":"Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","journal":"Blood","issue":"Blood. 2022 Aug 31:blood.2022016052. doi: 10.1182\/blood.2022016052. Online ahead of print.","author":"Mo F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, Brenner MK, Tkachev V, Mamonkin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36044667"},{"title01":"Mantle-Cell Lymphoma","title02":"Mantle-Cell Lymphoma","journal":"N Engl J Med","issue":"2022 Sep 15;387(11):1049.","author":"Yavorkovsky LL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36103422"},{"title01":"Mantle-Cell Lymphoma. Reply","title02":"Mantle-Cell Lymphoma. Reply","journal":"N Engl J Med","issue":"2022 Sep 15;387(11):1050.","author":"Armitage JO, Longo DL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36103423"},{"title01":"CNS prophylaxis for diffuse large B-cell lymphoma","title02":"CNS prophylaxis for diffuse large B-cell lymphoma","journal":"Lancet Oncol","issue":"2022 Sep;23(9):e416-e426.","author":"Eyre TA, Savage KJ, Cheah CY, El-Galaly TC, Lewis KL, McKay P, Wilson MR, Evens AM, Bobillo S, Villa D, Maurer MJ, Cwynarski K, Ferreri AJM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36055310"},{"title01":"Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?","title02":"Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Sep 1:JCO2201501. doi: 10.1200\/JCO.22.01501. Online ahead of print.","author":"Kahl BS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36049146"},{"title01":"Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant","title02":"Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Sep 6. doi: 10.1111\/bjh.18441. Online ahead of print.","author":"Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36068929"},{"title01":"COVID-19 infection in primary central nervous system lymphoma treatment: Who is most at risk?","title02":"COVID-19 infection in primary central nervous system lymphoma treatment: Who is most at risk?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 26. doi: 10.1111\/bjh.18416. Online ahead of print.","author":"Lim SH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36017936"},{"title01":"Link between disease status at 24\u2009months and mortality in follicular lymphoma","title02":"Link between disease status at 24\u2009months and mortality in follicular lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 26. doi: 10.1111\/bjh.18423. Online ahead of print.","author":"Rajam\u00e4ki A, Hujo M, Sund R, Prusila REI, Kuusisto MEL, Kuitunen H, Jantunen E, Mercadal S, Sorigue M, Sancho JM, Kuittinen O, Sunela K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36028946"},{"title01":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","title02":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 27. doi: 10.1111\/bjh.18418. Online ahead of print.","author":"Nakhoda S, Vistarop A, Wang YL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36029036"},{"title01":"Progression of CCND1- in situ mantle cell neoplasia to CCND1- mantle cell lymphoma","title02":"Progression of CCND1- in situ mantle cell neoplasia to CCND1- mantle cell lymphoma","journal":"Blood","issue":"2022 Sep 8;140(10):1182.","author":"Hegazy SE, Bailey NG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36074528"},{"title01":"MCD-DLBCL arises from germinal center B cells","title02":"MCD-DLBCL arises from germinal center B cells","journal":"Blood","issue":"2022 Sep 8;140(10):1058-1059.","author":"Wen R, Wang D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36074533"},{"title01":"Numerous B cells in a mediastinal mass, but not a\u00a0B-cell lymphoma","title02":"Numerous B cells in a mediastinal mass, but not a\u00a0B-cell lymphoma","journal":"Blood","issue":"2022 Aug 25;140(8):932.","author":"Venkataraman G, Alikhan MB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36006670"},{"title01":"CAR-T for follicular lymphoma: are we good to go?","title02":"CAR-T for follicular lymphoma: are we good to go?","journal":"Blood","issue":"2022 Aug 25;140(8):799-800.","author":"Gasiorowski R, Trotman J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36006675"},{"title01":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","title02":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 27:JCO2201504. doi: 10.1200\/JCO.22.01504. Online ahead of print.","author":"D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, Polepally AR, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36029527"},{"title01":"ATRA works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells","title02":"ATRA works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells","journal":"Haematologica","issue":"Haematologica. 2022 Sep 1. doi: 10.3324\/haematol.2021.281339. Online ahead of print.","author":"Garc\u00eda-Guerrero E, Rodr\u00edguez-Lobato LG, Sierro-Mart\u00ednez B, Danhof S, Bates S, Frenz S, Haertle L, G\u00f6tz R, Sauer M, Rasche L, Kort\u00fcm KM, P\u00e9rez-Sim\u00f3n JA, Einsele H, Hudecek M, Prommersberger SR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36047086"},{"title01":"Activation of lncRNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins","title02":"Activation of lncRNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins","journal":"Haematologica","issue":"Haematologica. 2022 Sep 8. doi: 10.3324\/haematol.2022.281167. Online ahead of print.","author":"Taiana E, Bandini C, Favasuli VK, Ronchetti D, Silvestris I, Puccio N, Todoerti K, Erratico S, Giannandrea D, Bolli N, Amodio N, Ciarrocchi A, Chiaramonte R, Torrente Y, Piva R, Neri A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36073514"},{"title01":"Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma","title02":"Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.281322. Online ahead of print.","author":"Asher S, Kazantzi A, Dekaj F, Steventon L, Khatun A, Ainley L, McMillan A, Rabin N, Wechalekar A, Sive J, Kyriakou C, Papanikolaou X, Xu K, Mahmood S, Wisniowski B, Lee L, Yong K, Popat R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005557"},{"title01":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia","title02":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia","journal":"N Engl J Med","issue":"2022 Sep 1;387(9):859.","author":"Merli P, Guzzo I, Locatelli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36053525"},{"title01":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia. Reply","title02":"Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia. Reply","journal":"N Engl J Med","issue":"2022 Sep 1;387(9):860.","author":"Bertaina A, Grimm PC, Weinberg K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36053526"},{"title01":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial","title02":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial","journal":"Leukemia","issue":"Leukemia. 2022 Sep 12. doi: 10.1038\/s41375-022-01693-z. Online ahead of print.","author":"Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, Burkhardt B, Classen CF, Claviez A, Corbacioglu S, Deubzer HE, Greil J, Gruhn B, G\u00fcng\u00f6r T, Kafa K, K\u00fchl JS, Lang P, Lange BS, Meisel R, M\u00fcller I, Sauer MG, Schlegel PG, Schulz A, Stachel D, Strahm B, Wawer A, Peters C, Albert MH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36097283"},{"title01":"Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions","title02":"Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Sep 7:JCO2201505. doi: 10.1200\/JCO.22.01505. Online ahead of print.","author":"Maiti A, Daver NG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36070541"},{"title01":"Mitigation of gastrointestinal graft versus host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination","title02":"Mitigation of gastrointestinal graft versus host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination","journal":"Haematologica","issue":"Haematologica. 2022 Sep 15. doi: 10.3324\/haematol.2022.281309. Online ahead of print.","author":"Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36106394"},{"title01":"Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival","title02":"Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival","journal":"Haematologica","issue":"Haematologica. 2022 Sep 8. doi: 10.3324\/haematol.2022.281495. Online ahead of print.","author":"Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36073516"},{"title01":"Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant","title02":"Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Sep 6. doi: 10.1111\/bjh.18441. Online ahead of print.","author":"Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36068929"},{"title01":"Impact of human leukocyte antigen mismatch on outcomes after unrelated bone marrow transplantation in paediatric patients: A retrospective analysis by the JSTCT HLA working group","title02":"Impact of human leukocyte antigen mismatch on outcomes after unrelated bone marrow transplantation in paediatric patients: A retrospective analysis by the JSTCT HLA working group","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 27. doi: 10.1111\/bjh.18425. Online ahead of print.","author":"Kato I, Sakaguchi H, Kato S, Sato M, Noguchi M, Yoshida N, Koh K, Koike T, Yanagimachi M, Kato K, Takahashi Y, Fujita N, Sato A, Hashii Y, Tabuchi K, Atsuta Y, Morishima S, Kanda J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36029121"},{"title01":"Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?","title02":"Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?","journal":"Leukemia","issue":"Leukemia. 2022 Sep 13. doi: 10.1038\/s41375-022-01699-7. Online ahead of print.","author":"Yang S, Kay NE, Shi M, Hanson CA, Gale RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36100641"},{"title01":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","title02":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","journal":"Leukemia","issue":"Leukemia. 2022 Sep 14. doi: 10.1038\/s41375-022-01698-8. Online ahead of print.","author":"Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Am\u00e9 S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Th\u00e9pot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36104395"},{"title01":"Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML","title02":"Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML","journal":"Leukemia","issue":"Leukemia. 2022 Sep 2. doi: 10.1038\/s41375-022-01687-x. Online ahead of print.","author":"Allert C, Waclawiczek A, Zimmermann SMN, G\u00f6llner S, Heid D, Janssen M, Renders S, Rohde C, Bauer M, Bruckmann M, Zinz R, Pauli C, Besenbeck B, Wickenhauser C, Trumpp A, Krijgsveld J, M\u00fcller-Tidow C, Blank MF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36056084"},{"title01":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","title02":"Current status and future perspectives in targeted therapy of NPM1<\/i>-mutated AML","journal":"Leukemia","issue":"Leukemia. 2022 Aug 25. doi: 10.1038\/s41375-022-01666-2. Online ahead of print.","author":"Ranieri R, Pianigiani G, Sciabolacci S, Perriello VM, Marra A, Cardinali V, Pierangeli S, Milano F, Gionfriddo I, Brunetti L, Martelli MP, Falini B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36008542"},{"title01":"Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia","title02":"Epigenomic profiling of glucocorticoid responses identifies cis<\/i>-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Aug 26. doi: 10.1038\/s41375-022-01685-z. Online ahead of print.","author":"Bergeron BP, Diedrich JD, Zhang Y, Barnett KR, Dong Q, Ferguson DC, Autry RJ, Yang W, Hansen BS, Smith C, Crews KR, Fan Y, Pui CH, Pruett-Miller SM, Relling MV, Yang JJ, Li C, Evans WE, Savic D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36028659"},{"title01":"Loss of AID exacerbates the malignant progression of CLL","title02":"Loss of AID exacerbates the malignant progression of CLL","journal":"Leukemia","issue":"Leukemia. 2022 Aug 30. doi: 10.1038\/s41375-022-01663-5. Online ahead of print.","author":"Lee AC, Pingali SR, Pinilla-Ibarz JA, Atchison ML, Koumenis C, Argon Y, Thomas-Tikhonenko A, De Trez C, Hu CA, Tang CA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36042317"},{"title01":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","title02":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Sep 6:S2352-3026(22)00225-3. doi: 10.1016\/S2352-3026(22)00225-3. Online ahead of print.","author":"Ghorashian S, Jacoby E, De Moerloose B, Rives S, Bonney D, Shenton G, Bader P, Bodmer N, Quintana AM, Herrero B, Algeri M, Locatelli F, Vettenranta K, Gonzalez B, Attarbaschi A, Harris S, Bourquin JP, Baruchel A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36084658"},{"title01":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","title02":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Sep 2:S2352-3026(22)00216-2. doi: 10.1016\/S2352-3026(22)00216-2. Online ahead of print.","author":"Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36063832"},{"title01":"Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial","title02":"Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Sep 9:JCO2200767. doi: 10.1200\/JCO.22.00767. Online ahead of print.","author":"Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, Deng L, Wang S, Lin D, Luo X, Zhang Q, Liu X, Li X, Liang X, Xie S, Qu H, Yu S, Zhou H, Shi P, Xuan L, Lin R, Liu H, Jin H, Sun J, Liu Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36084276"},{"title01":"Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in Tcell acute lymphoblastic leukemia","title02":"Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in Tcell acute lymphoblastic leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Sep 8. doi: 10.3324\/haematol.2022.280761. Online ahead of print.","author":"Lim FQ, Chan AS, Yokomori R, Huang XZ, Theardy MS, Yeoh AEJ, Tan SH, Sanda T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36073513"},{"title01":"Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population","title02":"Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population","journal":"Haematologica","issue":"Haematologica. 2022 Sep 8. doi: 10.3324\/haematol.2022.281386. Online ahead of print.","author":"Kockerols CCB, Janssen JJWM, Blijlevens NMA, Klein SK, Van Hussen-Daenen LGM, Van Gorkom GGY, Smit WM, Van Balen P, Biemond BJ, Cruijsen MJ, Corsten MF, Te Boekhorst PAW, Koene HR, Van Sluis GL, Cornelissen JJ, Westerweel PE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36073515"},{"title01":"Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival","title02":"Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival","journal":"Haematologica","issue":"Haematologica. 2022 Sep 8. doi: 10.3324\/haematol.2022.281495. Online ahead of print.","author":"Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36073516"},{"title01":"Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial","title02":"Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial","journal":"Haematologica","issue":"Haematologica. 2022 Sep 8. doi: 10.3324\/haematol.2022.281221. Online ahead of print.","author":"Stalder G, Suffiotti M, Segot A, Noto A, Pantaleo G, Spertini O, Obeid M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36073517"},{"title01":"An open-label, phase I\/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia","title02":"An open-label, phase I\/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.281128. Online ahead of print.","author":"Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW, Esteve J, Mondal S, R\u00fcter B, Burkard U, Osswald A, Blum W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005556"},{"title01":"Structure-function analysis of the role of megakaryoblastic leukemia 1 in megakaryocyte polyploidization","title02":"Structure-function analysis of the role of megakaryoblastic leukemia 1 in megakaryocyte polyploidization","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.280499. Online ahead of print.","author":"Reed FE, Eskow NM, Min E, Carlino M, Mancuso R, Kwon N, Smith EC, Larsuel ST, Wang L, Scanlon V, Krause DS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005559"},{"title01":"BCL6 inhibition ameliorates ruxolitinib resistance in CRLF2-rearranged acute lymphoblastic leukemia","title02":"BCL6 inhibition ameliorates ruxolitinib resistance in CRLF2-rearranged acute lymphoblastic leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.280879. Online ahead of print.","author":"Tsuzuki S, Yasuda T, Goto H, Maeda N, Akahane K, Inukai T, Yamamoto H, Karnan S, Ota A, Hyodo T, Konishi H, Hosokawa Y, Kiyoi H, Hayakawa F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005560"},{"title01":"Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia","title02":"Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 25. doi: 10.3324\/haematol.2022.281151. Online ahead of print.","author":"Sahoo BK, Lin YC, Tu CF, Lin CC, Liao WJ, Li FA, Li LH, Mou KY, Roffler SR, Wang SP, Yeh CT, Yao CY, Hou HA, Chou WC, Tien HF, Yang RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36005562"},{"title01":"The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment","title02":"The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 16. doi: 10.1111\/bjh.18404. Online ahead of print.","author":"Naik A, Gooley T, Loeb K, Soma L, Smith SD, Gopal A, Naresh KN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35973829"},{"title01":"Splenic diffuse red pulp small B-cell lymphoma with cyclin D3 expression","title02":"Splenic diffuse red pulp small B-cell lymphoma with cyclin D3 expression","journal":"Blood","issue":"2022 Aug 18;140(7):793.","author":"Ozkaya N, Jaffe ES.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35980678"},{"title01":"Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma","title02":"Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma","journal":"Blood","issue":"Blood. 2022 Aug 12:blood.2022016428. doi: 10.1182\/blood.2022016428. Online ahead of print.","author":"Vanden Bempt M, Debackere K, Demeyer S, Van Thillo Q, Meeuws N, Fernandez CP, Provost S, Mentens N, Jacobs K, Gielen O, Nittner D, Ogawa S, Kataoka K, Graux C, Tousseyn T, Cools J, Dierickx D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35960849"},{"title01":"Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma","title02":"Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma","journal":"Blood","issue":"Blood. 2022 Aug 17:blood.2022016056. doi: 10.1182\/blood.2022016056. Online ahead of print.","author":"Flerlage JE, Myers JR, Maciaszek JL, Oak N, Rashkin SR, Hui Y, Wang YD, Chen W, Wu G, Chang TC, Hamilton KV, Goldin LR, Rotunno M, Caporaso NE, Vogt A, Flamish D, Wyatt K, Liu J, Tucker MA, Mullighan CG, Nichols KE, Metzger ML, McMaster ML, Yang JJ, Rampersaud E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35977101"},{"title01":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","title02":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 12:JCO2102815. doi: 10.1200\/JCO.21.02815. Online ahead of print.","author":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35960908"},{"title01":"Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome","title02":"Transcriptional signature of TP53<\/i> biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 18. doi: 10.1111\/bjh.18410. Online ahead of print.","author":"De Ram\u00f3n C, Rojas EA, Cardona-Benavides IJ, Mateos MV, Corchete LA, Guti\u00e9rrez NC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35983648"},{"title01":"Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada","title02":"Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 10. doi: 10.1111\/bjh.18401. Online ahead of print.","author":"Mohyuddin GR, Sinnarajah A, Gayowsky A, Chan KKW, Seow H, Mian H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35949180"},{"title01":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial","title02":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial","journal":"Leukemia","issue":"Leukemia. 2022 Aug 16. doi: 10.1038\/s41375-022-01667-1. Online ahead of print.","author":"Zimmermann H, Koenecke C, Dreyling MH, Pott C, D\u00fchrsen U, Hahn D, Meidenbauer N, Hauser IA, Rummel MJ, Wolf D, Heuser M, Schmidt C, Schlattmann P, Ritgen M, Siebert R, Oschlies I, Anagnostopoulos I, Trappe RU.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35974101"},{"title01":"Circulating endothelial cells and the study of vascular injury in children undergoing hematopoietic stem cell transplant","title02":"Circulating endothelial cells and the study of vascular injury in children undergoing hematopoietic stem cell transplant","journal":"Haematologica","issue":"Haematologica. 2022 Aug 18. doi: 10.3324\/haematol.2022.280788. Online ahead of print.","author":"Sabulski A, Abdullah S, Luebbering N, Aunins B, Castillo C, Lake K, Duell A, Strecker L, Giordullo L, Broomhead W, Dimeo S, Odegard EA, Blackard JT, Ziady A, Seif AE, Dandoy CE, Laskin BL, Jodele S, Davies SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35979718"},{"title01":"Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group","title02":"Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 21. doi: 10.1111\/bjh.18408. Online ahead of print.","author":"Xu L, Lu Y, Hu S, Li C, Tang Y, Wang H, Yan J, Chen J, Liu S, Sun Y, Wu X, Lin F, Lu P, Huang X; Chinese Blood and Marrow Transplantation Registry Group (CBMTR).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35989315"},{"title01":"Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity","title02":"Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity","journal":"Blood","issue":"Blood. 2022 Aug 18:blood.2022015677. doi: 10.1182\/blood.2022015677. Online ahead of print.","author":"Wang J, Chang CY, Yang X, Zhou F, Liu J, Zhu S, Yu XZ, Liu C, O'Sullivan TE, Xie P, Feng Z, Hu W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35981499"},{"title01":"Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation","title02":"Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation","journal":"Blood","issue":"Blood. 2022 Aug 19:blood.2022016926. doi: 10.1182\/blood.2022016926. Online ahead of print.","author":"Vallet N, Le Grand S, Bondeelle L, Hoareau B, Corneau A, Bouteiller D, Tournier S, Lew-Derivry L, Bohineust A, Tourret M, Gibert D, Mayeur E, Itzykson RA, Pacchiardi K, Ingram B, Cassonnet S, Lepage P, Peffault de Latour R, Socie G, Bergeron A, Michonneau D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35984904"},{"title01":"Donor natural killer cells trigger production of beta-2-microglobulin to enhance post bone marrow transplant immunity","title02":"Donor natural killer cells trigger production of beta-2-microglobulin to enhance post bone marrow transplant immunity","journal":"Blood","issue":"Blood. 2022 Aug 5:blood.2021015297. doi: 10.1182\/blood.2021015297. Online ahead of print.","author":"Ruggeri L, Urbani E, Chiasserini D, Susta F, Orvietani PL, Burchielli E, Ciardelli S, Sola R, Bruscoli S, Cardinale A, Pierini A, Piersma S, Pasquino S, Locatelli F, Ramarli D, Velardi E, Binaglia L, Jimenez C, Hollander G, Velardi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35984965"},{"title01":"Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome","title02":"Pre-transplant FLT3<\/i>-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome","journal":"Blood","issue":"Blood. 2022 Aug 12:blood.2022016567. doi: 10.1182\/blood.2022016567. Online ahead of print.","author":"Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, Potter N, Jovanovic J, Runglall M, Chua CC, Bajel A, Ritchie DS, Gray K, Yeoh ZH, McBean M, Gilkes AF, Thomas I, Johnson S, Russell NH, Wei AH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35960851"},{"title01":"Preservation of fecal microbiome is associated with reduced severity of Graft-versus-Host Disease","title02":"Preservation of fecal microbiome is associated with reduced severity of Graft-versus-Host Disease","journal":"Blood","issue":"Blood. 2022 Aug 15:blood.2021015352. doi: 10.1182\/blood.2021015352. Online ahead of print.","author":"Burgos da Silva M, Ponce DM, Dai A, Devlin SM, Gomes AL, Moore GF, Slingerland J, Shouval R, Armijo GK, DeWolf S, Fei T, Clurman A, Fontana E, Amoretti LA, Wright RJ, Andrlova H, Miltiadous O, Perales MA, Taur Y, Peled JU, van den Brink MRM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35969834"},{"title01":"Osteoprogenitor SFRP1 prevents exhaustion of hematopoietic stem cells via PP2A-PR72\/130-mediated regulation of p300","title02":"Osteoprogenitor SFRP1 prevents exhaustion of hematopoietic stem cells via PP2A-PR72\/130-mediated regulation of p300","journal":"Haematologica","issue":"Haematologica. 2022 Aug 11. doi: 10.3324\/haematol.2022.280760. Online ahead of print.","author":"Hettler F, Schreck C, Marquez SR, Engleitner T, Vilne B, Landspersky T, Weidner H, Hausinger R, Mishra R, Oellinger R, Rauner M, Naumann R, Peschel C, Bassermann F, Rad R, Istvanffy R, Oostendorp RAJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35950533"},{"title01":"Circulating endothelial cells and the study of vascular injury in children undergoing hematopoietic stem cell transplant","title02":"Circulating endothelial cells and the study of vascular injury in children undergoing hematopoietic stem cell transplant","journal":"Haematologica","issue":"Haematologica. 2022 Aug 18. doi: 10.3324\/haematol.2022.280788. Online ahead of print.","author":"Sabulski A, Abdullah S, Luebbering N, Aunins B, Castillo C, Lake K, Duell A, Strecker L, Giordullo L, Broomhead W, Dimeo S, Odegard EA, Blackard JT, Ziady A, Seif AE, Dandoy CE, Laskin BL, Jodele S, Davies SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35979718"},{"title01":"Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group","title02":"Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 21. doi: 10.1111\/bjh.18408. Online ahead of print.","author":"Xu L, Lu Y, Hu S, Li C, Tang Y, Wang H, Yan J, Chen J, Liu S, Sun Y, Wu X, Lin F, Lu P, Huang X; Chinese Blood and Marrow Transplantation Registry Group (CBMTR).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35989315"},{"title01":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","title02":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","journal":"Blood","issue":"Blood. 2022 Aug 18:blood.2022015474. doi: 10.1182\/blood.2022015474. Online ahead of print.","author":"Wang D, Sun Z, Zhu X, Zheng X, Zhou Y, Lu Y, Yan P, Wang H, Liu H, Jin J, Zhu H, Sun R, Wang Y, Fu B, Tian Z, Wei H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35981475"},{"title01":"Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation","title02":"Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation","journal":"Blood","issue":"Blood. 2022 Aug 19:blood.2022016926. doi: 10.1182\/blood.2022016926. Online ahead of print.","author":"Vallet N, Le Grand S, Bondeelle L, Hoareau B, Corneau A, Bouteiller D, Tournier S, Lew-Derivry L, Bohineust A, Tourret M, Gibert D, Mayeur E, Itzykson RA, Pacchiardi K, Ingram B, Cassonnet S, Lepage P, Peffault de Latour R, Socie G, Bergeron A, Michonneau D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35984904"},{"title01":"The use of pluripotent stem cells to generate diagnostic tools for transfusion medicine","title02":"The use of pluripotent stem cells to generate diagnostic tools for transfusion medicine","journal":"Blood","issue":"Blood. 2022 Aug 17:blood.2022015883. doi: 10.1182\/blood.2022015883. Online ahead of print.","author":"An HH, Gagne AL, Maguire JA, Pavani G, Abdulmalik O, Gadue P, French DL, Westhoff CM, Chou ST.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35977098"},{"title01":"Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study","title02":"Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 23:JCO2102476. doi: 10.1200\/JCO.21.02476. Online ahead of print.","author":"Platzbecker U, G\u00f6tze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschl\u00e4gel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35998303"},{"title01":"Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group","title02":"Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 21. doi: 10.1111\/bjh.18408. Online ahead of print.","author":"Xu L, Lu Y, Hu S, Li C, Tang Y, Wang H, Yan J, Chen J, Liu S, Sun Y, Wu X, Lin F, Lu P, Huang X; Chinese Blood and Marrow Transplantation Registry Group (CBMTR).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35989315"},{"title01":"Does G6PD deficiency cause further damage to red blood cells of patients with sickle cell anaemia?","title02":"Does G6PD deficiency cause further damage to red blood cells of patients with sickle cell anaemia?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 16. doi: 10.1111\/bjh.18417. Online ahead of print.","author":"Esperti S, Boisson C, Robert M, Nader E, Cibiel A, Renoux C, Horrand F, Gauthier A, Poutrel S, Joly P, Connes P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35973746"},{"title01":"The role of iron in chronic inflammatory diseases – from mechanisms to treatment options in Anemia of Inflammation","title02":"The role of iron in chronic inflammatory diseases – from mechanisms to treatment options in Anemia of Inflammation","journal":"Blood","issue":"Blood. 2022 Aug 22:blood.2021013472. doi: 10.1182\/blood.2021013472. Online ahead of print.","author":"Marques O, Weiss G, Muckenthaler MU.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35994752"},{"title01":"Impact of emerging ACA on survival in chronic myeloid leukemia (CML)","title02":"Impact of emerging ACA on survival in chronic myeloid leukemia (CML)","journal":"Leukemia","issue":"Leukemia. 2022 Aug 23. doi: 10.1038\/s41375-022-01681-3. Online ahead of print.","author":"Hehlmann R, Lauseker M, Voskanyan A, Fabarius A, Haferlach C, Hochhaus A, Sau\u00dfele S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35999258"},{"title01":"Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial","title02":"Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial","journal":"Leukemia","issue":"Leukemia. 2022 Aug 23. doi: 10.1038\/s41375-022-01680-4. Online ahead of print.","author":"Yen R, Grasedieck S, Wu A, Lin H, Su J, Rothe K, Nakamoto H, Forrest DL, Eaves CJ, Jiang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35999259"},{"title01":"Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia","title02":"Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Aug 23. doi: 10.1038\/s41375-022-01678-y. Online ahead of print.","author":"Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Th\u00f6lken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, M\u00fcnch C, Brandts CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35999260"},{"title01":"Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia-a Grand Ouest Against Leukemia (GOAL) study","title02":"Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia-a Grand Ouest Against Leukemia (GOAL) study","journal":"Leukemia","issue":"Leukemia. 2022 Aug 12. doi: 10.1038\/s41375-022-01677-z. Online ahead of print.","author":"Desprez C, Riou J, Peterlin P, Marchand T, Couturier MA, Villate A, Mear JB, Chevalier P, Guillerm G, Gyan E, Schmidt-Tanguy A, Walter RB, Hunault-Berger M, Orvain C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35962057"},{"title01":"Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults","title02":"Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults","journal":"Leukemia","issue":"Leukemia. 2022 Aug 16. doi: 10.1038\/s41375-022-01671-5. Online ahead of print.","author":"Arniani S, Pierini V, Pellanera F, Matteucci C, Di Giacomo D, Bardelli V, Quintini M, Mavridou E, Lema Fernandez AG, Nardelli C, Moretti M, Gorello P, Crescenzi B, Romoli S, Beacci D, Cerrano M, Fracchiolla N, Sica S, Forghieri F, Giglio F, Dargenio M, Elia L, La Starza R, Mecucci C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35974102"},{"title01":"Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial","title02":"Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Aug 18:S2352-3026(22)00211-3. doi: 10.1016\/S2352-3026(22)00211-3. Online ahead of print.","author":"Cramer P, F\u00fcrstenau M, Robrecht S, Giza A, Zhang C, Fink AM, Fischer K, Langerbeins P, Al-Sawaf O, Tausch E, Schneider C, Schetelig J, Dreger P, B\u00f6ttcher S, Kreuzer KA, Schilhabel A, Ritgen M, Br\u00fcggemann M, Kneba M, Stilgenbauer S, Eichhorst B, Hallek M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35988545"},{"title01":"The evolving multi-agent options for chronic lymphocytic leukaemia treatment","title02":"The evolving multi-agent options for chronic lymphocytic leukaemia treatment","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Aug 18:S2352-3026(22)00221-6. doi: 10.1016\/S2352-3026(22)00221-6. Online ahead of print.","author":"de la Serna J, Baumann T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35988548"},{"title01":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","title02":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T cell immunotherapy against FLT3<\/i>-mutant acute myeloid leukemia and KMT2A<\/i>-rearranged acute lymphoblastic leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 11. doi: 10.3324\/haematol.2022.281456. Online ahead of print.","author":"Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35950535"},{"title01":"In vivo stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute leukemia","title02":"In vivo<\/i> stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 18. doi: 10.3324\/haematol.2022.281390. Online ahead of print.","author":"Van Trimpont M, Schalk AM, De Visser Y, Nguyen HA, Reunes L, Vandemeulebroecke K, Peeters E, Su Y, Lee H, Lorenzi PL, Chan WK, Mondelaers V, De Moerloose B, Lammens T, Goossens S, Van Vlierberghe P, Lavie A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35979719"},{"title01":"Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis","title02":"Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 23. doi: 10.1111\/bjh.18428. Online ahead of print.","author":"Qiang X, Chen S, Chen X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35996972"},{"title01":"Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper","title02":"Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 24. doi: 10.1111\/bjh.18369. Online ahead of print.","author":"Dennis M, Copland M, Kaur H, Kell J, Nikolousis E, Mehta P, Palanicawandar R, Potter V, Raj K, Thomas I, Wilson A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36000944"},{"title01":"Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia","title02":"Prominence of NUDT15<\/i> genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 12. doi: 10.1111\/bjh.18405. Online ahead of print.","author":"Tanaka Y, Urayama KY, Mori M, Arakawa Y, Hasegawa D, Noguchi Y, Yanagimachi M, Keino D, Ota S, Akahane K, Inukai T, Hangai M, Kawaguchi T, Takagi M, Koh K, Matsuda F, Manabe A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35961941"},{"title01":"What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?","title02":"What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 16. doi: 10.1111\/bjh.18413. Online ahead of print.","author":"Fordham NJ, Bartram J, Ghorashian S, O'Connor D, Taylor A, Sibson K, Rao A, Pavasovic V, Cheng D, Ancliff P, Vora A, Samarasinghe S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35974444"},{"title01":"A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia","title02":"A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10<\/i> to acute megakaryoblastic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 17. doi: 10.1111\/bjh.18414. Online ahead of print.","author":"Li T, Wu P, Wang A, Chen M, Fu M, Wang H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35978554"},{"title01":"DDX41: the poster child for familial AML","title02":"DDX41<\/i>: the poster child for familial AML","journal":"Blood","issue":"2022 Aug 18;140(7):667-669.","author":"Rio-Machin A, Fitzgibbon J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35980681"},{"title01":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","title02":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","journal":"Blood","issue":"Blood. 2022 Aug 18:blood.2022015474. doi: 10.1182\/blood.2022015474. Online ahead of print.","author":"Wang D, Sun Z, Zhu X, Zheng X, Zhou Y, Lu Y, Yan P, Wang H, Liu H, Jin J, Zhu H, Sun R, Wang Y, Fu B, Tian Z, Wei H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35981475"},{"title01":"TARGETING FLT3 BY NEW-GENERATION ANTIBODY-DRUG-CONJUGATE IN COMBINATION WITH KINASE INHIBITORS FOR TREATMENT OF AML","title02":"TARGETING FLT3 BY NEW-GENERATION ANTIBODY-DRUG-CONJUGATE IN COMBINATION WITH KINASE INHIBITORS FOR TREATMENT OF AML","journal":"Blood","issue":"Blood. 2022 Aug 18:blood.2021015246. doi: 10.1182\/blood.2021015246. Online ahead of print.","author":"Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig AE, Rohrbacher L, Herold T, Subklewe M, G\u00f6tze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35981498"},{"title01":"Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity","title02":"Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity","journal":"Blood","issue":"Blood. 2022 Aug 18:blood.2022015677. doi: 10.1182\/blood.2022015677. Online ahead of print.","author":"Wang J, Chang CY, Yang X, Zhou F, Liu J, Zhu S, Yu XZ, Liu C, O'Sullivan TE, Xie P, Feng Z, Hu W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35981499"},{"title01":"Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities","title02":"Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities","journal":"Blood","issue":"Blood. 2022 Aug 18:blood.2022015414. doi: 10.1182\/blood.2022015414. Online ahead of print.","author":"Cappelli LV, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L, Barcia Dur\u00e1n JG, Zamponi N, Melnick AM, Boccalatte F, Tam W, Elemento O, Chiaretti S, Guarini AR, Fo\u00e0 R, Cerchietti L, Rafii S, Inghirami GG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35981563"},{"title01":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","title02":"Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","journal":"Blood","issue":"Blood. 2022 Aug 19:blood.2022015668. doi: 10.1182\/blood.2022015668. Online ahead of print.","author":"Poplineau M, Platet N, Mazuel A, H\u00e9rault L, N'guyen L, Koide S, Nakajima-Takagi Y, Kuribayashi W, Carbuccia N, Haboub L, Vernerey J, Oshima M, Birnbaum D, Iwama A, Duprez E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35984905"},{"title01":"Dietary methionine starvation impairs acute myeloid leukemia progression","title02":"Dietary methionine starvation impairs acute myeloid leukemia progression","journal":"Blood","issue":"Blood. 2022 Aug 19:blood.2022017575. doi: 10.1182\/blood.2022017575. Online ahead of print.","author":"Cunningham A, Erdem A, Alshamleh I, Geugien M, Pruis M, Pereira-Martins DA, van den Heuvel F, Wierenga A, Ten Berge HA, Dennebos R, van den Boom V, Hogeling SM, Weinh\u00e4user I, Knops R, de Blaauw P, Heiner-Fokkema MR, Woolthuis C, G\u00fcnther U, Rego EM, Martens J, Jansen JH, Schwalbe H, Huls G, Schuringa JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35984907"},{"title01":"Glutamine and CLL: ready for prime time?","title02":"Glutamine and CLL: ready for prime time?","journal":"Blood","issue":"2022 Aug 11;140(6):528-529.","author":"Deaglio S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35951344"},{"title01":"Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine","title02":"Prognostic impact of NPM1<\/i> and FLT3<\/i> mutations in patients with AML in first remission treated with oral azacitidine","journal":"Blood","issue":"Blood. 2022 Aug 12:blood.2022016293. doi: 10.1182\/blood.2022016293. Online ahead of print.","author":"D\u00f6hner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne BS, See WL, Ugidos M, Risue\u00f1o A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35960871"},{"title01":"Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial","title02":"Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial","journal":"Leukemia","issue":"Leukemia. 2022 Aug 13. doi: 10.1038\/s41375-022-01658-2. Online ahead of print.","author":"Freeman CL, Pararajalingam P, Jin L, Balasubramanian S, Jiang A, Xu W, Grau M, Zapukhlyak M, Boyle M, Hodkinson B, Schaffer M, Enny C, Deshpande S, Sun S, Vermeulen J, Morin RD, Scott DW, Lenz G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35963941"},{"title01":"A prognostic survival nomogram for persons with extra-nodal natural killer-\/T-cell lymphoma","title02":"A prognostic survival nomogram for persons with extra-nodal natural killer-\/T-cell lymphoma","journal":"Leukemia","issue":"Leukemia. 2022 Aug 15. doi: 10.1038\/s41375-022-01679-x. Online ahead of print.","author":"Wang H, Fu BB, Wuxiao ZJ, Li YJ, Huang L, Ma J, Zhai ZM, Guo J, Wu YB, Xu ZS, Feng J, Zhou SS, Chen TT, Chen XG, Li GW, Liu TZ, Huang HB, Zheng RH, Li YH, Tao HF, Zi FM, Wu F, Wang J, Zeng H, Fu CB, Gale RP, Xia ZJ, Liang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35970944"},{"title01":"Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma","title02":"Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 11:JCO2200597. doi: 10.1200\/JCO.22.00597. Online ahead of print.","author":"Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35952327"},{"title01":"Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma","title02":"Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 22. doi: 10.1111\/bjh.18406. Online ahead of print.","author":"Binkley MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35993185"},{"title01":"Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients","title02":"Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 24. doi: 10.1111\/bjh.18426. Online ahead of print.","author":"Isidori A, Loscocco F, Visani G, Paolasini S, Scalzulli P, Musto P, Perrone T, Guarini A, Pastore D, Mazza P, Tonialini L, Pavone V, De Santis G, Tarantini G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36002151"},{"title01":"Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia","title02":"Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 12. doi: 10.1111\/bjh.18399. Online ahead of print.","author":"Jessa R, Chien N, Villa D, Freeman CL, Slack GW, Savage KJ, Scott DW, Sehn LH, Song KW, Gerrie AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35961783"},{"title01":"Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2\u2009years after allogeneic bone marrow transplant","title02":"Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2\u2009years after allogeneic bone marrow transplant","journal":"Br J Haematol","issue":"2022 Aug;198(4):668-679.","author":"Murray SM, Barbanti M, Campbell C, Brown A, Chen L, Dhanapal J, Tseu B, Pervaiz O, Peters L, Springett S, Danby R, Adele S, Phillips E, Malone T, Amini A, Stafford L, Deeks AS, Dunachie S, Klenerman P, Peniket A, Barnes E, Kesavan M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35655410"},{"title01":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR\/CMWP of\u00a0EBMT analysis","title02":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR\/CMWP of\u00a0EBMT analysis","journal":"Br J Haematol","issue":"2022 Aug;198(4):785-789.","author":"Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hern\u00e1ndez-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658101"},{"title01":"A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease","title02":"A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease","journal":"Br J Haematol","issue":"2022 Aug;198(4):729-739.","author":"Pratta M, Paczesny S, Socie G, Barkey N, Liu H, Owens S, Arbushites MC, Schroeder MA, Howell MD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35689489"},{"title01":"The clinical influence of preformed nonspecific anti-HLA antibodies on single-unit umbilical cord blood transplantation in patients with haematological malignancies","title02":"The clinical influence of preformed nonspecific anti-HLA antibodies on single-unit umbilical cord blood transplantation in patients with haematological malignancies","journal":"Br J Haematol","issue":"2022 Aug;198(4):e63-e66.","author":"Wu Y, Tang B, Song K, Sun G, Tu M, Wan X, Yao W, Qiang P, Pan T, Ding P, Zhu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35715873"},{"title01":"What complements complement in transplant-associated thrombotic microangiopathy?","title02":"What complements complement in transplant-associated thrombotic microangiopathy?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 9. doi: 10.1111\/bjh.18402. Online ahead of print.","author":"Sabulski A, Jodele S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35942659"},{"title01":"Prebiotic galactooligosaccharides interact with mouse gut microbiota to attenuate acute graft-versus-host disease","title02":"Prebiotic galactooligosaccharides interact with mouse gut microbiota to attenuate acute graft-versus-host disease","journal":"Blood","issue":"Blood. 2022 Aug 5:blood.2021015178. doi: 10.1182\/blood.2021015178. Online ahead of print.","author":"Holmes ZC, Tang H, Liu C, Bush AT, Neubert BC, Jiao Y, Covington M, Cardona DM, Kirtley MC, Chen BJ, Chao NJ, David LA, Sung AD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35930748"},{"title01":"The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells","title02":"The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells","journal":"Leukemia","issue":"2022 Aug;36(8):1969-1979.","author":"Vi\u00f1ado AC, Calvo IA, Cenzano I, Olaverri D, Cocera M, San Martin-Uriz P, Romero JP, Vilas-Zornoza A, Vera L, Gomez-Cebrian N, Puchades-Carrasco L, Lisi-Vega LE, Apaolaza I, Valera P, Guruceaga E, Granero-Molto F, Ripalda-Cemborain P, Luck TJ, Bullinger L, Planes FJ, Rifon JJ, M\u00e9ndez-Ferrer S, Yusuf RZ, Pardo-Saganta A, Prosper F, Saez B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35618797"},{"title01":"REDD1 is a gatekeeper of murine hematopoietic stem cell functions during stress responses","title02":"REDD1 is a gatekeeper of murine hematopoietic stem cell functions during stress responses","journal":"Leukemia","issue":"2022 Aug;36(8):2140-2143.","author":"Barroca V, Henry E, Dechamps N, Renou L, Chaintreuil P, Kulkarni R, Devanand S, Jacquel A, Robert G, Auberger P, Pflumio F, Arcangeli ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35641638"},{"title01":"Nuclear translocation of TFE3 under hypoxia enhances the engraftment of human hematopoietic stem cells","title02":"Nuclear translocation of TFE3 under hypoxia enhances the engraftment of human hematopoietic stem cells","journal":"Leukemia","issue":"2022 Aug;36(8):2144-2148.","author":"Wang X, Cooper S, Broxmeyer HE, Kapur R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35732828"},{"title01":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","title02":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1066-1077.","author":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839786"},{"title01":"Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues","title02":"Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues","journal":"Lancet Haematol","issue":"2022 Aug;9(8):e605-e614.","author":"Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, Shaw BE, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35901845"},{"title01":"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy","title02":"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy","journal":"J Clin Oncol","issue":"2022 Aug 1;40(22):2447-2457.","author":"Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, Whitaker S, Rambaldi A; OMS721-TMA-001 Study Group Members.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35439028"},{"title01":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","title02":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 4. doi: 10.3324\/haematol.2022.281585. Online ahead of print.","author":"Orvain C, Wilson JA, Fang M, Sandmaier BM, Rodr\u00edguez-Arbol\u00ed E, Wood BL, Othus M, Appelbaum FR, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35924583"},{"title01":"m(6)A reader Ythdf3 protects hematopoietic stem cell integrity under stress by promoting the translation of Foxm1 and Asxl1 transcripts","title02":"m(6)A reader Ythdf3 protects hematopoietic stem cell integrity under stress by promoting the translation of Foxm1<\/i> and Asxl1<\/i> transcripts","journal":"Haematologica","issue":"107(8):1922-1927","author":"Dang Q, Wu Q, Yu F, Sheng Y, Yu C, Song G, Paulsen K, Lyu J, Qian Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34818872"},{"title01":"A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo","title02":"A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro<\/i> and in vivo<\/i>","journal":"Haematologica","issue":"107(8):1786-1795","author":"Arruda LCM, Stikvoort A, Lambert M, Jin L, Rivera LS, Alves RMP, De Moura TR, Mim C, Lehmann S, Axelsson-Robertson R, Dick JE, Mattsson J, \u00d6nfelt B, Carlsten M, Uhlin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35142149"},{"title01":"The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant","title02":"The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant","journal":"Br J Haematol","issue":"2022 Aug;198(4):625-640.","author":"Kricke S, Rao K, Adams S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35421255"},{"title01":"Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia","title02":"Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia","journal":"Br J Haematol","issue":"2022 Aug;198(4):780-784.","author":"Genthon A, Dragoi D, Memoli M, Hirsch P, Favale F, Suner L, Chaquin M, Boncoeur P, Marjanovic Z, Bonnin A, Sestili S, Dulery R, Malard F, Brissot E, Banet A, van de Wyngaert Z, Vekhoff A, Delhommeau F, Mohty M, Legrand O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35615877"},{"title01":"Favourable outcomes of double-hit\/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience","title02":"Favourable outcomes of double-hit\/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience","journal":"Br J Haematol","issue":"2022 Aug;198(4):776-779.","author":"Str\u00fc\u00dfmann T, Glatzki F, Engelhardt M, Mertelsmann R, Duyster J, Finke J, Marks R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35620830"},{"title01":"The impact of COVID-19 on related-donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey","title02":"The impact of COVID-19 on related-donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey","journal":"Br J Haematol","issue":"2022 Aug;198(4):e51-e53.","author":"Wolf J, Lee J, Pearce R, Wilson M, Snowden JA, Orchard K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35655329"},{"title01":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR\/CMWP of\u00a0EBMT analysis","title02":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR\/CMWP of\u00a0EBMT analysis","journal":"Br J Haematol","issue":"2022 Aug;198(4):785-789.","author":"Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hern\u00e1ndez-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658101"},{"title01":"Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease","title02":"Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease","journal":"Br J Haematol","issue":"2022 Aug;198(4):740-744.","author":"Sharma A, Leonard A, West K, Gossett JM, Uchida N, Panch S, Stroncek D, Poston L, Akel S, Hankins JS, Fitzhugh C, Hsieh MM, Kang G, Tisdale JF, Weiss MJ, Zheng Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35737751"},{"title01":"p57Kip2 regulates embryonic blood stem cells by controlling sympathoadrenal progenitor expansion","title02":"p57Kip2 regulates embryonic blood stem cells by controlling sympathoadrenal progenitor expansion","journal":"Blood","issue":"2022 Aug 4;140(5):464-477.","author":"Kapeni C, Nitsche L, Kilpatrick AM, Wilson NK, Xia K, Mirshekar-Syahkal B, Chandrakanthan V, Malouf C, Pimanda JE, G\u00f6ttgens B, Kirschner K, Tomlinson SR, Ottersbach K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35653588"},{"title01":"p57Kip2 indirectly regulates AGM HSCs","title02":"p57Kip2 indirectly regulates AGM HSCs","journal":"Blood","issue":"2022 Aug 4;140(5):411-412.","author":"Mao X, Li L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35925643"},{"title01":"Specification of hematopoietic stem cells in mammalian embryos: a rare or frequent event?","title02":"Specification of hematopoietic stem cells in mammalian embryos: a rare or frequent event?","journal":"Blood","issue":"2022 Jul 28;140(4):309-320.","author":"Ganuza M, Clements W, McKinney-Freeman S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35737920"},{"title01":"Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia","title02":"Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia","journal":"Leukemia","issue":"Leukemia. 2022 Aug 5. doi: 10.1038\/s41375-022-01654-6. Online ahead of print.","author":"Kelkka T, Tyster M, Lundgren S, Feng X, Kerr C, Hosokawa K, Huuhtanen J, Ker\u00e4nen M, Patel B, Kawakami T, Maeda Y, Nieminen O, Kasanen T, Aronen P, Yadav B, Rajala H, Nakazawa H, Jaatinen T, Hellstr\u00f6m-Lindberg E, Ogawa S, Ishida F, Nishikawa H, Nakao S, Maciejewski J, Young NS, Mustjoki S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35927326"},{"title01":"COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria","title02":"COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria","journal":"Lancet Haematol","issue":"2022 Aug;9(8):e553-e556.","author":"Pike A, McKinley C, Forrest B, Scott R, Charlton E, Scott E, Zhakata T, Harland M, Clarke D, Davies JR, Toogood A, Houghton N, Youngs N, Barnfield C, Richards S, Payne D, Arnold L, Munir T, Muus P, Griffin M, Kelly RJ, Hillmen P, Newton D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35780797"},{"title01":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","title02":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Jul 27:S2352-3026(22)00206-X. doi: 10.1016\/S2352-3026(22)00206-X. Online ahead of print.","author":"DeZern AE, Eapen M, Wu J, Talano JA, Solh M, D\u00e1vila Salda\u00f1a BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35907408"},{"title01":"Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future","title02":"Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Jul 27:S2352-3026(22)00242-3. doi: 10.1016\/S2352-3026(22)00242-3. Online ahead of print.","author":"Frieri C, Marano L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35907409"},{"title01":"Images from the Haematologica Atlas of Hematologic Cytology: congenital dyserythropoietic anemia type II","title02":"Images from the Haematologica Atlas of Hematologic Cytology: congenital dyserythropoietic anemia type II","journal":"Haematologica","issue":"2022 Aug 1;107(8):1736.","author":"Invernizzi R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35912722"},{"title01":"Diamond-Blackfan anaemia with iron overload: A serious issue","title02":"Diamond-Blackfan anaemia with iron overload: A serious issue","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 5. doi: 10.1111\/bjh.18393. Online ahead of print.","author":"Quarello P, Ramenghi U, Fagioli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35929529"},{"title01":"Maternal iron deficiency anaemia in pregnancy: Lessons from a national audit","title02":"Maternal iron deficiency anaemia in pregnancy: Lessons from a national audit","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 3. doi: 10.1111\/bjh.18391. Online ahead of print.","author":"Churchill D, Ali H, Moussa M, Donohue C, Pavord S, Robinson SE, Cheshire K, Wilson P, Grant-Casey J, Stanworth SJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35922080"},{"title01":"Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia","title02":"Germline PTPN13<\/i> mutations in patients with bone marrow failure and acute lymphoblastic leukemia","journal":"Leukemia","issue":"36(8):2132-2135","author":"Moshiri H, Cabrera Riofr\u00edo DA, Lim YJ, Lauhasurayotin S, Manisterski M, Elhasid R, Bonilla FA, Dhanraj S, Armstrong RN, Li H, Scherer SW, Hern\u00e1ndez-Hern\u00e1ndez A, Dror Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35643866"},{"title01":"Menstrual problems in chronic immune thrombocytopenia: A\u00a0monthly challenge – a cohort study and review","title02":"Menstrual problems in chronic immune thrombocytopenia: A\u00a0monthly challenge – a cohort study and review","journal":"Br J Haematol","issue":"2022 Aug;198(4):753-764.","author":"van Dijk WEM, Punt MC, van Galen KPM, van Leeuwen J, Lely AT, Schutgens REG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35662003"},{"title01":"Empagliflozin modulates CD4+ T-cell differentiation via metabolic reprogramming in immune thrombocytopenia","title02":"Empagliflozin modulates CD4+<\/sup> T-cell differentiation via metabolic reprogramming in immune thrombocytopenia","journal":"Br J Haematol","issue":"2022 Aug;198(4):765-775.","author":"Qin J, Liu Q, Liu A, Leng S, Wang S, Li C, Ma J, Peng J, Xu M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35675486"},{"title01":"Should dexamethasone alone or in combination be the initial steroid for adult ITP: Still a relevant question","title02":"Should dexamethasone alone or in combination be the initial steroid for adult ITP: Still a relevant question","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 3. doi: 10.1111\/bjh.18398. Online ahead of print.","author":"Skopec B, Bussel JB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35922885"},{"title01":"CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL","title02":"CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL","journal":"Leukemia","issue":"2022 Aug;36(8):2050-2063.","author":"Montes-Mojarro IA, Steinhilber J, Griessinger CM, Rau A, Gersmann AK, Kohlhofer U, Fallier-Becker P, Liang HC, Hofmann U, Haag M, Klapper W, Schaeffeler E, Pichler BJ, Schwab M, Fend F, Bonzheim I, Quintanilla-Martinez L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35676454"},{"title01":"Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer\/T-cell lymphoma","title02":"Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer\/T-cell lymphoma","journal":"Leukemia","issue":"2022 Aug;36(8):2064-2075.","author":"Dong G, Liu X, Wang L, Yin W, Bouska A, Gong Q, Shetty K, Chen L, Sharma S, Zhang J, Lome-Maldonado C, Quintanilla-Martinez L, Li Y, Song JY, Zhang W, Shi Y, Wang J, Kong L, Wu X, Wang J, Liu HG, Kong L, Sun W, Liu W, Wang L, McKeithan TW, Iqbal J, Chan WC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35697790"},{"title01":"Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma","title02":"Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma","journal":"Lancet Oncol","issue":"2022 Aug;23(8):967-969.","author":"Buske C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35803285"},{"title01":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","title02":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1055-1065.","author":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35803286"},{"title01":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","title02":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1031-1043.","author":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, \u0160imkovi\u010d M, Shadman M, \u00d6sterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trn\u011bn\u00fd M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35810754"},{"title01":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","title02":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1066-1077.","author":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839786"},{"title01":"Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma","title02":"Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 10:JCO2200843. doi: 10.1200\/JCO.22.00843. Online ahead of print.","author":"Morschhauser F, Nastoupil L, Feugier P, Schiano de Colella JM, Tilly H, Palomba ML, Bachy E, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Le Gouill S, Daguindau N, Guidez S, Pica GM, Garc\u00eda-Sancho AM, L\u00f3pez-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, Andr\u00e9 M, Kalung W, Sehn LH, Izutsu K, Cartron G, Gkasiamis A, Crowe R, Xerri L, Fowler NH, Salles G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35947804"},{"title01":"Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma","title02":"Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 10:JCO2102613. doi: 10.1200\/JCO.21.02613. Online ahead of print.","author":"de Vries S, Haaksma ML, J\u00f3\u017awiak K, Schaapveld M, Hodgson DC, Lugtenburg PJ, Krol ADG, Petersen EJ, van Spronsen DJ, Ahmed S, Hauptmann M, Aleman BMP, van Leeuwen FE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35947813"},{"title01":"Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and\/or BCL6 rearrangements characterized by whole-exome sequencing","title02":"Mutational landscape of high-grade B-cell lymphoma with MYC-<\/i>, BCL2<\/i> and\/or BCL6<\/i> rearrangements characterized by whole-exome sequencing","journal":"Haematologica","issue":"107(8):1850-1863.","author":"K\u00fcnstner A, Witte HM, Riedl J, Bernard V, St\u00f6lting S, Merz H, Olschewski V, Peter W, Ketzer J, Busch Y, Trojok P, Bubnoff NV, Busch H, Feller AC, Gebauer N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34788985"},{"title01":"Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS","title02":"Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS","journal":"Haematologica","issue":"2022 Aug 1;107(8):1864-1879.","author":"Wai CMM, Chen S, Phyu T, Fan S, Leong SM, Zheng W, Low LCY, Choo SN, Lee CK, Chung TH, Ban KHK, Ghosh S, Lie S, Kato S, Nakamura S, Takahashi E, Ko YH, Khoury JD, Chuang SS, Au-Yeung RKH, Tan SY, Lim ST, Ong CK, Ho YH, Poon LM, De Mel S, Jeyasekharan AD, Chng WJ, Otto F, Quintanilla-Martinez L, Zanardi F, Iannelli F, Tripodo C, Pitt JJ, Ng SB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35021606"},{"title01":"Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance","title02":"Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance","journal":"Haematologica","issue":"2022 Aug 1;107(8):1880-1890.","author":"Fisher KE, Ferguson LS, Coffey AM, Merritt BY, Curry JL, Marcogliese AN, Major AM, Kamdar KY, Lopez-Terrada DH, Curry CV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35081690"},{"title01":"Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory\/relapse diffuse large B-cell lymphoma","title02":"Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory\/relapse diffuse large B-cell lymphoma","journal":"Haematologica","issue":"2022 Aug 1;107(8):1928-1932.","author":"Quivoron C, Tarabay A, Michot JM, Pag\u00e8s A, Lecourt H, Aup\u00e9rin A, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Verg\u00e9 V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35320922"},{"title01":"Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma","title02":"Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma","journal":"Haematologica","issue":"2022 Aug 1;107(8):1999-2003.","author":"Kim M, Hwang HS, Yoon DH, Chun SM, Go H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354255"},{"title01":"Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis","title02":"Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis","journal":"Haematologica","issue":"Haematologica. 2022 Jul 28. doi: 10.3324\/haematol.2022.281351. Online ahead of print.","author":"Falini L, Venanzi A, Tini V, Innocente A, Ballanti S, Saldi S, Sivolella S, Pierini A, Aristei C, Tiacci E, Perriello VM, Falini B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35899391"},{"title01":"Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia","title02":"Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia","journal":"Br J Haematol","issue":"2022 Aug;198(4):684-692.","author":"Zhu K, Jamroz A, Huang S, Villa D, Freeman CL, Scott DW, Slack G, Sehn LH, Connors JM, Toze CL, Savage KJ, Gerrie AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35567407"},{"title01":"Favourable outcomes of double-hit\/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience","title02":"Favourable outcomes of double-hit\/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience","journal":"Br J Haematol","issue":"2022 Aug;198(4):776-779.","author":"Str\u00fc\u00dfmann T, Glatzki F, Engelhardt M, Mertelsmann R, Duyster J, Finke J, Marks R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35620830"},{"title01":"Skin manifestations of intravascular adult T-cell leukaemia\/lymphoma","title02":"Skin manifestations of intravascular adult T-cell leukaemia\/lymphoma","journal":"Br J Haematol","issue":"2022 Aug;198(4):618.","author":"Katayama S, Hiraishi T, Ota M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35759250"},{"title01":"Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group","title02":"Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 9. doi: 10.1111\/bjh.18396. Online ahead of print.","author":"Steffanoni S, Calimeri T, Laurenge A, Fox CP, Soussain C, Grommes C, Tisi MC, Boot J, Crosbie N, Visco C, Arcaini L, Chaganti S, Sassone MC, Alencar A, Armiento D, Romano I, Dietrich J, Itchaki G, Bruna R, Fracchiolla NS, Arletti L, Venditti A, Booth S, Musto P, Hoang Xuan K, Batchelor TT, Cwynarski K, Ferreri AJM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35945164"},{"title01":"United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma","title02":"United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 2. doi: 10.1111\/bjh.18384. Online ahead of print.","author":"Tarantelli C, Bertoni F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35917107"},{"title01":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","title02":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","journal":"Blood","issue":"2022 Aug 4;140(5):419-437.","author":"Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34758074"},{"title01":"Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma","title02":"Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma","journal":"Blood","issue":"2022 Aug 4;140(5):491-503.","author":"Jain MD, Ziccheddu B, Coughlin CA, Faramand R, Griswold AJ, Reid KM, Menges M, Zhang Y, Cen L, Wang X, Hussaini M, Landgren O, Davila ML, Schatz JH, Locke FL, Maura F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35476848"},{"title01":"Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma","title02":"Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma","journal":"Blood","issue":"2022 Aug 4;140(5):504-515.","author":"Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35512184"},{"title01":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","title02":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","journal":"Blood","issue":"2022 Jul 28;140(4):349-358.","author":"Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Fante MA, Schroers R, Bayir L, Borchmann P, Buecklein V, Hasenkamp J, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35316325"},{"title01":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","title02":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","journal":"Blood","issue":"2022 Jul 28;140(4):303-308.","author":"Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35580172"},{"title01":"EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements","title02":"EBV-positive high-grade B-cell lymphoma with MYC and BCL6<\/i> rearrangements","journal":"Blood","issue":"2022 Jul 28;140(4):406.","author":"Craig A, Wen KW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35900784"},{"title01":"Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma","title02":"Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma","journal":"Blood","issue":"Blood. 2022 Aug 1:blood.2022016747. doi: 10.1182\/blood.2022016747. Online ahead of print.","author":"Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, Mei MG, Popplewell L, Siddiqi T, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35914220"},{"title01":"Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","title02":"Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","journal":"Blood","issue":"Blood. 2022 Aug 2:blood.2021015184. doi: 10.1182\/blood.2021015184. Online ahead of print.","author":"Cichocki F, Goodridge J, Bjordahl R, Mahmood S, Davis ZB, Gaidarova S, Abujarour R, Groff B, Witty AD, Wang H, Tuininga K, Kodal B, Felices M, Bonello GB, Huffman J, Dailey T, Lee TT, Walcheck B, Valamehr B, Miller JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35917442"},{"title01":"Clonal germinal center B cells function as a niche for T-cell lymphoma","title02":"Clonal germinal center B cells function as a niche for T-cell lymphoma","journal":"Blood","issue":"Blood. 2022 Aug 3:blood.2022015451. doi: 10.1182\/blood.2022015451. Online ahead of print.","author":"Fujisawa M, Nguyen TB, Abe Y, Suehara Y, Fukumoto K, Suma S, Makishima K, Kaneko C, Nguyen YTM, Usuki K, Narita K, Matsue K, Nakamura N, Ishikawa S, Miura F, Ito T, Suzuki A, Suzuki Y, Mizuno S, Takahashi S, Chiba S, Sakata-Yanagimoto M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35921527"},{"title01":"Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas","title02":"Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas","journal":"Blood","issue":"Blood. 2022 Aug 3:blood.2022015646. doi: 10.1182\/blood.2022015646. Online ahead of print.","author":"Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35921533"},{"title01":"T-Cell Engagers – Modern Immune-Based Therapies for Multiple Myeloma","title02":"T-Cell Engagers – Modern Immune-Based Therapies for Multiple Myeloma","journal":"N Engl J Med","issue":"2022 Aug 11;387(6):558-561.","author":"Mailankody S, Landgren O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35947712"},{"title01":"Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period","title02":"Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period","journal":"Leukemia","issue":"2022 Aug;36(8):2136-2139.","author":"Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35761025"},{"title01":"Calvarium indentations in multiple myeloma and CAR T-cell therapy","title02":"Calvarium indentations in multiple myeloma and CAR T-cell therapy","journal":"Lancet","issue":"2022 Jul 30;400(10349):391.","author":"Munoz J, Larsen J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35908571"},{"title01":"Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?","title02":"Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 9:JCO2200504. doi: 10.1200\/JCO.22.00504. Online ahead of print.","author":"Casey M, Odhiambo L, Aggarwal N, Shoukier M, Garner J, Islam KM, Cortes JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35944216"},{"title01":"Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities","title02":"Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities","journal":"Haematologica","issue":"2022 Aug 1;107(8):1891-1901.","author":"Giesen N, Paramasivam N, Toprak UH, Huebschmann D, Xu J, Uhrig S, Samur M, B\u00e4hr S, Fr\u00f6hlich M, Mughal SS, Mai EK, Jauch A, M\u00fcller-Tidow C, Brors B, Munshi N, Goldschmidt H, Weinhold N, Schlesner M, Raab MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35045690"},{"title01":"A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","title02":"A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","journal":"Haematologica","issue":"2022 Aug 1;107(8):1960-1965.","author":"Yang M, Zhang W, Yu K, Wang P, Jiang H, Chen L, Meng H, Weng Y, Tao R, Huang X, Xing C, Wang H, Wan J, Wang S, Dai L, Hendrix AY, Xiao J, Wang W, Ma H, Hao S, Jin J, Li Z, Jiang S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35443566"},{"title01":"Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia","title02":"Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia","journal":"Leukemia","issue":"2022 Aug;36(8):2002-2008.","author":"Orvain C, Othus M, Johal G, Hunault-Berger M, Appelbaum FR, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35660798"},{"title01":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","title02":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1078-1086.","author":"Carroll RP, Boyer M, Gebski V, Hockley B, Johnston JK, Kireta S, Tan H, Taylor A, Wyburn K, Zalcberg JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35809595"},{"title01":"Managing immune checkpoint inhibition in transplant recipients","title02":"Managing immune checkpoint inhibition in transplant recipients","journal":"Lancet Oncol","issue":"2022 Aug;23(8):969-971.","author":"Lebb\u00e9 C, Biard L, Delyon J, Zuber J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35809596"},{"title01":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","title02":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1066-1077.","author":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839786"},{"title01":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","title02":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Jul 27:S2352-3026(22)00206-X. doi: 10.1016\/S2352-3026(22)00206-X. Online ahead of print.","author":"DeZern AE, Eapen M, Wu J, Talano JA, Solh M, D\u00e1vila Salda\u00f1a BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35907408"},{"title01":"Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future","title02":"Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Jul 27:S2352-3026(22)00242-3. doi: 10.1016\/S2352-3026(22)00242-3. Online ahead of print.","author":"Frieri C, Marano L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35907409"},{"title01":"Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia","title02":"Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 5:JCO2201177. doi: 10.1200\/JCO.22.01177. Online ahead of print.","author":"Socie G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35930761"},{"title01":"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy","title02":"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy","journal":"J Clin Oncol","issue":"2022 Aug 1;40(22):2447-2457.","author":"Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, Whitaker S, Rambaldi A; OMS721-TMA-001 Study Group Members.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35439028"},{"title01":"Minnesota acute GvHD risk score predicts survival at onset of GvHD after PTCy prophylaxis","title02":"Minnesota acute GvHD risk score predicts survival at onset of GvHD after PTCy prophylaxis","journal":"Haematologica","issue":"Haematologica. 2022 Jul 28. doi: 10.3324\/haematol.2022.281269. Online ahead of print.","author":"Ardizzoia F, Lorentino F, Bruno A, Marktel S, Giglio F, Clerici D, Farina F, Mastaglio S, Piemontese S, Assanelli AA, Carrabba MG, Bernardi M, Corti C, Peccatori J, Ciceri F, Greco R, Lupo-Stanghellini MT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35899390"},{"title01":"Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic SCT is predictive of subsequent relapse and survival","title02":"Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic SCT is predictive of subsequent relapse and survival","journal":"Haematologica","issue":"Haematologica. 2022 Aug 4. doi: 10.3324\/haematol.2021.280497. Online ahead of print.","author":"Verma K, Croft W, Pearce H, Zuo J, Stephens C, Nunnick J, Kinsella FA, Malladi R, Moss P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35924575"},{"title01":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","title02":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 4. doi: 10.3324\/haematol.2022.281585. Online ahead of print.","author":"Orvain C, Wilson JA, Fang M, Sandmaier BM, Rodr\u00edguez-Arbol\u00ed E, Wood BL, Othus M, Appelbaum FR, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35924583"},{"title01":"The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant","title02":"The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant","journal":"Br J Haematol","issue":"2022 Aug;198(4):625-640.","author":"Kricke S, Rao K, Adams S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35421255"},{"title01":"Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia","title02":"Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia","journal":"Br J Haematol","issue":"2022 Aug;198(4):780-784.","author":"Genthon A, Dragoi D, Memoli M, Hirsch P, Favale F, Suner L, Chaquin M, Boncoeur P, Marjanovic Z, Bonnin A, Sestili S, Dulery R, Malard F, Brissot E, Banet A, van de Wyngaert Z, Vekhoff A, Delhommeau F, Mohty M, Legrand O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35615877"},{"title01":"Favourable outcomes of double-hit\/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience","title02":"Favourable outcomes of double-hit\/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience","journal":"Br J Haematol","issue":"2022 Aug;198(4):776-779.","author":"Str\u00fc\u00dfmann T, Glatzki F, Engelhardt M, Mertelsmann R, Duyster J, Finke J, Marks R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35620830"},{"title01":"The impact of COVID-19 on related-donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey","title02":"The impact of COVID-19 on related-donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey","journal":"Br J Haematol","issue":"2022 Aug;198(4):e51-e53.","author":"Wolf J, Lee J, Pearce R, Wilson M, Snowden JA, Orchard K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35655329"},{"title01":"Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55\u2009985 patients from the National Cancer Database","title02":"Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55\u2009985 patients from the National Cancer Database","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 28. doi: 10.1111\/bjh.18381. Online ahead of print.","author":"Alsouqi A, Rothenberger SD, Boyiadzis M, Lontos K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35899627"},{"title01":"Management of a patient with acute myeloid leukaemia with a diagnosis of type 2 von Willebrand disease and a novel variant within the von Willebrand factor (VWF) gene","title02":"Management of a patient with acute myeloid leukaemia with a diagnosis of type 2 von Willebrand disease and a novel variant within the von Willebrand factor (VWF<\/i>) gene","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 29. doi: 10.1111\/bjh.18390. Online ahead of print.","author":"Dillon J, Mykytiv V, Keenan C, Mullaney B, Orfali N, Ryan K, Duggan C, Crowley MP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35903954"},{"title01":"Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA)","title02":"Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA)","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 29. doi: 10.1111\/bjh.18359. Online ahead of print.","author":"Breccia M, Olimpieri PP, Celant S, Olimpieri O, Pane F, Iurlo A, Summa V, Corradini P, Russo P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35904979"},{"title01":"Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia","title02":"Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 2. doi: 10.1111\/bjh.18373. Online ahead of print.","author":"Albertsen BK, Lynggaard LS, Schmiegelow K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35917113"},{"title01":"A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management","title02":"A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Aug 3. doi: 10.1111\/bjh.18397. Online ahead of print.","author":"Andersson NG, Rathe M, M\u00f8lle I, Jarvis KB, Hoffmann M, Huurre A, Joelsson J, Albertsen BK, Lohi O, L\u00e5ngstr\u00f6m S, Overgaard U, Saulyte Trakymiene S, Veps\u00e4l\u00e4inen K, Vogt H, Ranta S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35922061"},{"title01":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","title02":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","journal":"Blood","issue":"2022 Aug 4;140(5):445-450.","author":"Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35588468"},{"title01":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study","title02":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study","journal":"Blood","issue":"2022 Aug 4;140(5):516-520.","author":"Li SQ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Lv M, Tang FF, Mo XD, Liu YR, Liu KY, Chang YJ, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35613411"},{"title01":"CLL and COVID-19: light at the end of the tunnel?","title02":"CLL and COVID-19: light at the end of the tunnel?","journal":"Blood","issue":"2022 Aug 4;140(5):407-409.","author":"Scarf\u00f2 L, Herishanu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35925645"},{"title01":"AML: making residual disease more measurable","title02":"AML: making residual disease more measurable","journal":"Blood","issue":"2022 Aug 4;140(5):415-417.","author":"Voso MT, Buccisano F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35925646"},{"title01":"Single cell genomics in AML: extending the frontiers of AML research","title02":"Single cell genomics in AML: extending the frontiers of AML research","journal":"Blood","issue":"Blood. 2022 Aug 4:blood.2021014670. doi: 10.1182\/blood.2021014670. Online ahead of print.","author":"Ediriwickrema A, Gentles AJ, Majeti R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35926108"},{"title01":"Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia – approaches and molecular insights","title02":"Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia – approaches and molecular insights","journal":"Blood","issue":"Blood. 2022 Aug 4:blood.2022016954. doi: 10.1182\/blood.2022016954. Online ahead of print.","author":"Iacobucci I, Witkowski MT, Mullighan CG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35926109"},{"title01":"Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy","title02":"Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy","journal":"Blood","issue":"Blood. 2022 Aug 5:blood.2022016183. doi: 10.1182\/blood.2022016183. Online ahead of print.","author":"Handa S, Lee JO, Derkach A, Stone RM, Saven A, Altman JK, Grever MR, Rai KR, Shukla M, Vemuri S, Montoya S, Taylor J, Abdel-Wahab O, Tallman MS, Park JH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35930750"},{"title01":"Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia","title02":"Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia","journal":"Blood","issue":"2022 Jul 28;140(4):335-348.","author":"Tracy SI, Venkatesh H, Hekim C, Heltemes-Harris LM, Knutson TP, Bachanova V, Farrar MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35275990"},{"title01":"Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients","title02":"Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients","journal":"Blood","issue":"2022 Jul 28;140(4):401-405.","author":"Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, Byrd JC, Marth GT, Stephens DM, Woyach JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35476648"},{"title01":"Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","title02":"Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","journal":"Blood","issue":"Blood. 2022 Aug 2:blood.2021015184. doi: 10.1182\/blood.2021015184. Online ahead of print.","author":"Cichocki F, Goodridge J, Bjordahl R, Mahmood S, Davis ZB, Gaidarova S, Abujarour R, Groff B, Witty AD, Wang H, Tuininga K, Kodal B, Felices M, Bonello GB, Huffman J, Dailey T, Lee TT, Walcheck B, Valamehr B, Miller JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35917442"},{"title01":"Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy","title02":"Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3<\/i>mut+ AML Ineligible for Intensive Chemotherapy","journal":"Blood","issue":"Blood. 2022 Aug 2:blood.2021014586. doi: 10.1182\/blood.2021014586. Online ahead of print.","author":"Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini CB, Patkowska EN, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35917453"},{"title01":"MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R\/R CLL","title02":"MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R\/R CLL","journal":"Blood","issue":"Blood. 2022 Aug 3:blood.2022016901. doi: 10.1182\/blood.2022016901. Online ahead of print.","author":"Scarfo L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, Moia R, Deodato M, Ferrario A, Motta M, Reda G, Sancetta R, Coscia M, Rivela P, Laurenti L, Varettoni M, Perotta E, Capasso A, Ranghetti P, Colia M, Ghia P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35921541"},{"title01":"A Better Treatment for Advanced-Stage Hodgkin’s Lymphoma?","title02":"A Better Treatment for Advanced-Stage Hodgkin’s Lymphoma?","journal":"N Engl J Med","issue":"2022 Jul 28;387(4):370-372.","author":"Longo DL, Armitage JO.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35830618"},{"title01":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma","title02":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma","journal":"N Engl J Med","issue":"2022 Jul 28;387(4):310-320.","author":"Ansell SM, Radford J, Connors JM, D\u0142ugosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35830649"},{"title01":"A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma","title02":"A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma","journal":"Leukemia","issue":"Leukemia. 2022 Aug 6. doi: 10.1038\/s41375-022-01670-6. Online ahead of print.","author":"Mendeville M, Janssen J, Kim Y, van Dijk E, de Jong D, Ylstra B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35933522"},{"title01":"Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia","title02":"Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 5:JCO2201177. doi: 10.1200\/JCO.22.01177. Online ahead of print.","author":"Socie G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35930761"},{"title01":"Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?","title02":"Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Aug 9:JCO2200504. doi: 10.1200\/JCO.22.00504. Online ahead of print.","author":"Casey M, Odhiambo L, Aggarwal N, Shoukier M, Garner J, Islam KM, Cortes JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35944216"},{"title01":"Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission","title02":"Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission","journal":"Haematologica","issue":"Haematologica. 2022 Aug 4. doi: 10.3324\/haematol.2022.280740. Online ahead of print.","author":"Dulucq S, Hayette S, Cayuela JM, Bauduer F, Chabane K, Chevallier P, Cony-Makhoul P, Flandrin-Gresta P, Jeune CL, Bris YL, Legros L, Maisonneuve H, Roy L, Mahon FX, Sloma I, Rea D, Nicolini FE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35924576"},{"title01":"Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia","title02":"Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 4. doi: 10.3324\/haematol.2022.280676. Online ahead of print.","author":"Sourdeau E, Suner L, Memoli M, Genthon A, Feger F, Soret L, Abermil N, Heuberger L, Bilhou-Nabera C, Guermouche H, Favale F, Lapusan S, Chaquin M, Hirschauer C, Mohty M, Legrand O, Delhommeau F, Hirsch P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35924580"},{"title01":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","title02":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 4. doi: 10.3324\/haematol.2022.281585. Online ahead of print.","author":"Orvain C, Wilson JA, Fang M, Sandmaier BM, Rodr\u00edguez-Arbol\u00ed E, Wood BL, Othus M, Appelbaum FR, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35924583"},{"title01":"Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia","title02":"Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Aug 4. doi: 10.3324\/haematol.2022.281445. Online ahead of print.","author":"Palmieri R, Othus M, Cheng GS, Buccisano F, Paterno G, Maurillo L, Del Principe MI, Sconocchia G, Venditti A, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35924584"},{"title01":"Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy","title02":"Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy","journal":"Haematologica","issue":"2022 Aug 1;107(8):1773-1785.","author":"Ihlow J, Gross S, Busack L, Fl\u00f6rcken A, Jesse J, Schwarz M, Neuendorff NR, Br\u00fcnneck AV, Anagnostopoulos I, T\u00fcrkmen S, Blau IW, Burmeister T, Horst D, Bullinger L, Westermann J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34758607"},{"title01":"Kinetics matter: prognostic implications of early bone marrow assessment in acute myeloid leukemia","title02":"Kinetics matter: prognostic implications of early bone marrow assessment in acute myeloid leukemia","journal":"Haematologica","issue":"2022 Aug 1;107(8):1741-1742.","author":"Perner F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34758611"},{"title01":"The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements","title02":"The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements","journal":"Haematologica","issue":"2022 Aug 1;107(8):1758-1772.","author":"Grasedieck S, Cabantog A, MacPhee L, Im J, Ruess C, Demir B, Sperb N, R\u00fccker FG, D\u00f6hner K, Herold T, Pollack JR, Bullinger L, Rouhi A, Kuchenbauer F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34854277"},{"title01":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia","title02":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia","journal":"Haematologica","issue":"2022 Aug 1;107(8):1746-1757.","author":"Bride KL, Hu H, Tikhonova A, Fuller TJ, Vincent TL, Shraim R, Li MM, Carroll WL, Raetz EA, Aifantis I, Teachey DT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34937317"},{"title01":"B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia","title02":"B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia","journal":"Haematologica","issue":"2022 Aug 1;107(8):1796-1814.","author":"Schmid VK, Khadour A, Ahmed N, Brandl C, Nitschke L, Rajewsky K, Jumaa H, Hobeika E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35021605"},{"title01":"A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo","title02":"A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro<\/i> and in vivo<\/i>","journal":"Haematologica","issue":"107(8):1786-1795","author":"Arruda LCM, Stikvoort A, Lambert M, Jin L, Rivera LS, Alves RMP, De Moura TR, Mim C, Lehmann S, Axelsson-Robertson R, Dick JE, Mattsson J, \u00d6nfelt B, Carlsten M, Uhlin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35142149"},{"title01":"Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case","title02":"Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case","journal":"Haematologica","issue":"2022 Aug 1;107(8):1994-1998.","author":"Sk\u00e5nland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, Tj\u00f8nnfjord GE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35236056"},{"title01":"The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era","title02":"The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era","journal":"Haematologica","issue":"2022 Aug 1;107(8):1940-1943.","author":"Kockerols CCB, Geelen I, Levin MD, Janssen JJWM, Dinmohamed AG, Hoogendoorn M, Cornelissen JJ, Westerweel PE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354254"},{"title01":"COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report","title02":"COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report","journal":"Haematologica","issue":"2022 Aug 1;107(8):1955-1959.","author":"Chiaretti S, Bonifacio M, Agrippino R, Giglio F, Annunziata M, Curti A, Principe MID, Salutari P, Scium\u00e8 M, Delia M, Armenio M, Mancini V, Mul\u00e8 A, Grimaldi F, Rege-Cambrin G, Santoro L, Lussana F, Chiusolo P, Pasciolla C, Scattolin AM, Cerrano M, Ciccone M, Defina M, Forghieri F, Mazzone C, Piccini M, Ferrara F, Pizzolo G, Fo\u00e0 R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35443561"},{"title01":"Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia","title02":"Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia","journal":"Haematologica","issue":"2022 Aug 1;107(8):1971-1976.","author":"Hohtari H, Pallisgaard N, Kankainen M, Ellonen P, Br\u00fcck O, Siitonen T, S\u00e4ily M, Sinisalo M, Py\u00f6r\u00e4l\u00e4 M, It\u00e4l\u00e4-Remes M, Koskenvesa P, Elonen E, Mustjoki S, Porkka K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35484650"},{"title01":"Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China","title02":"Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China","journal":"Haematologica","issue":"2022 Aug 1;107(8):1966-1970.","author":"Chen Y, Liu Z, Zou J, Wang D, He W, Meng L, Cheng F, Zhang Y, Li W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35484651"},{"title01":"Improving the anti-acute myeloid leukemia activity of CD123-specific Engager T cells by MyD88 and CD40 costimulation","title02":"Improving the anti-acute myeloid leukemia activity of CD123-specific Engager T cells by MyD88 and CD40 costimulation","journal":"Haematologica","issue":"Haematologica. 2022 Jul 28. doi: 10.3324\/haematol.2021.279301. Online ahead of print.","author":"Vaidya A, Doherty E, Wu X, Huang S, Hebbar N, Thanekar U, Bonifant CL, Cheng C, Gottschalk S, Velasquez MP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35899386"},{"title01":"Analysis of rare driving events in pediatric acute myeloid leukemia","title02":"Analysis of rare driving events in pediatric acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Jul 28. doi: 10.3324\/haematol.2021.280250. Online ahead of print.","author":"Noort S, Oosterwijk JV, Ma J, Garfinkle EAR, Nance S, Walsh M, Song G, Reinhardt D, Pigazzi M, Locatelli F, Hasle H, Abrahamsson J, Jarosova M, Kelaidi C, Polychronopoulou S, Van den Heuvel-Eibrink MM, Fornerod M, Gruber TA, Zwaan CM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35899387"},{"title01":"PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?","title02":"PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?","journal":"Haematologica","issue":"Haematologica. 2022 Jul 28. doi: 10.3324\/haematol.2022.281266. Online ahead of print.","author":"Skanland SS, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35899388"},{"title01":"Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis","title02":"Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis","journal":"Haematologica","issue":"Haematologica. 2022 Jul 28. doi: 10.3324\/haematol.2022.281351. Online ahead of print.","author":"Falini L, Venanzi A, Tini V, Innocente A, Ballanti S, Saldi S, Sivolella S, Pierini A, Aristei C, Tiacci E, Perriello VM, Falini B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35899391"},{"title01":"Pure erythroid leukaemia mimicking metastatic carcinoma","title02":"Pure erythroid leukaemia mimicking metastatic carcinoma","journal":"Br J Haematol","issue":"2022 Aug;198(4):617.","author":"Laura CS, Ana FM, In\u00e9s LH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35560227"},{"title01":"Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia","title02":"Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia","journal":"Br J Haematol","issue":"2022 Aug;198(4):684-692.","author":"Zhu K, Jamroz A, Huang S, Villa D, Freeman CL, Scott DW, Slack G, Sehn LH, Connors JM, Toze CL, Savage KJ, Gerrie AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35567407"},{"title01":"Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia","title02":"Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia","journal":"Br J Haematol","issue":"2022 Aug;198(4):780-784.","author":"Genthon A, Dragoi D, Memoli M, Hirsch P, Favale F, Suner L, Chaquin M, Boncoeur P, Marjanovic Z, Bonnin A, Sestili S, Dulery R, Malard F, Brissot E, Banet A, van de Wyngaert Z, Vekhoff A, Delhommeau F, Mohty M, Legrand O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35615877"},{"title01":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR\/CMWP of\u00a0EBMT analysis","title02":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR\/CMWP of\u00a0EBMT analysis","journal":"Br J Haematol","issue":"2022 Aug;198(4):785-789.","author":"Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hern\u00e1ndez-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658101"},{"title01":"Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia","title02":"Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"2022 Aug;198(4):790-793.","author":"Mulligan SP, Opat S, Marlton P, Kuss B, Gerungan P, Puig A, McGeachie M, Tam CS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35702012"},{"title01":"Skin manifestations of intravascular adult T-cell leukaemia\/lymphoma","title02":"Skin manifestations of intravascular adult T-cell leukaemia\/lymphoma","journal":"Br J Haematol","issue":"2022 Aug;198(4):618.","author":"Katayama S, Hiraishi T, Ota M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35759250"},{"title01":"Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients","title02":"Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients","journal":"Leukemia","issue":"Leukemia. 2022 Aug 5. doi: 10.1038\/s41375-022-01664-4. Online ahead of print.","author":"Mostofi N, Shaw C, Walter RB, Percival MM, Estey EH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35931729"},{"title01":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","title02":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","journal":"Leukemia","issue":"Leukemia. 2022 Aug 6. doi: 10.1038\/s41375-022-01668-0. Online ahead of print.","author":"Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M, Cazzaniga G, Cario G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35933523"},{"title01":"An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia","title02":"An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Aug 9. doi: 10.1038\/s41375-022-01662-6. Online ahead of print.","author":"Kong W, He L, Zhu J, Br\u00fcck O, Porkka K, Heckman CA, Zhu S, Aittokallio T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35945345"},{"title01":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","title02":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","journal":"Leukemia","issue":"2022 Aug;36(8):1961-1968.","author":"Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V, Kossida S, Belessi C, Rosenquist R, Ghia P, Langerak AW, Davi F, Stamatopoulos K; ERIC, the European Research Initiative on CLL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35614318"},{"title01":"The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells","title02":"The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells","journal":"Leukemia","issue":"2022 Aug;36(8):1969-1979.","author":"Vi\u00f1ado AC, Calvo IA, Cenzano I, Olaverri D, Cocera M, San Martin-Uriz P, Romero JP, Vilas-Zornoza A, Vera L, Gomez-Cebrian N, Puchades-Carrasco L, Lisi-Vega LE, Apaolaza I, Valera P, Guruceaga E, Granero-Molto F, Ripalda-Cemborain P, Luck TJ, Bullinger L, Planes FJ, Rifon JJ, M\u00e9ndez-Ferrer S, Yusuf RZ, Pardo-Saganta A, Prosper F, Saez B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35618797"},{"title01":"Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication","title02":"Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication","journal":"Leukemia","issue":"2022 Aug;36(8):1990-2001.","author":"Man CH, Zeng X, Lam W, Ng TCC, Kwok TH, Dang KCC, Leung TWY, Ng NKL, Lam SSY, Cher CY, Leung AYH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35624145"},{"title01":"Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia","title02":"Germline PTPN13<\/i> mutations in patients with bone marrow failure and acute lymphoblastic leukemia","journal":"Leukemia","issue":"36(8):2132-2135","author":"Moshiri H, Cabrera Riofr\u00edo DA, Lim YJ, Lauhasurayotin S, Manisterski M, Elhasid R, Bonilla FA, Dhanraj S, Armstrong RN, Li H, Scherer SW, Hern\u00e1ndez-Hern\u00e1ndez A, Dror Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35643866"},{"title01":"Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy","title02":"Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy","journal":"Leukemia","issue":"2022 Aug;36(8):2042-2049.","author":"Zhang XS, Gale RP, Li ZY, Zhang MY, Huang XJ, Jiang Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35650426"},{"title01":"Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia","title02":"Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia","journal":"Leukemia","issue":"2022 Aug;36(8):2002-2008.","author":"Orvain C, Othus M, Johal G, Hunault-Berger M, Appelbaum FR, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35660798"},{"title01":"Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies","title02":"Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies","journal":"Leukemia","issue":"2022 Aug;36(8):1951-1960.","author":"Zarnegar-Lumley S, Caldwell KJ, Rubnitz JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35668109"},{"title01":"Novel mitochondria-targeting compounds selectively kill human leukemia cells","title02":"Novel mitochondria-targeting compounds selectively kill human leukemia cells","journal":"Leukemia","issue":"2022 Aug;36(8):2009-2021.","author":"Panina SB, Pei J, Baran N, Tjahjono E, Patel S, Alatrash G, Konoplev S, Stolbov LA, Poroikov VV, Konopleva M, Kirienko NV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35672446"},{"title01":"Remodeling of the m(6)A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages","title02":"Remodeling of the m(6)A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages","journal":"Leukemia","issue":"2022 Aug;36(8):2121-2124.","author":"Bueno-Costa A, Pi\u00f1eyro D, Garc\u00eda-Prieto CA, Ortiz-Barahona V, Martinez-Verbo L, Webster NA, Andrews B, Kol N, Avrahami C, Moshitch-Moshkovitz S, Rechavi G, Esteller M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35681051"},{"title01":"A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials","title02":"A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials","journal":"Leukemia","issue":"2022 Aug;36(8):2022-2031.","author":"Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35688939"},{"title01":"Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia","title02":"Cooperation between KDM6B<\/i> overexpression and TET2<\/i> deficiency in the pathogenesis of chronic myelomonocytic leukemia","journal":"Leukemia","issue":"36(8):2097-2107","author":"Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35697791"},{"title01":"Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial","title02":"Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial","journal":"Leukemia","issue":"2022 Aug;36(8):2125-2128.","author":"von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, F\u00fcrstenau M, Illmer T, Klaproth H, Tausch E, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, B\u00f6ttcher S, Eichhorst BF, Hallek M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35752657"},{"title01":"Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML","title02":"Combinatorial genetics reveals the Dock1-Rac2<\/i> axis as a potential target for the treatment of NPM1;Cohesin<\/i> mutated AML","journal":"Leukemia","issue":"36(8):2032-2041","author":"Meyer AE, Stelloh C, Pulakanti K, Burns R, Fisher JB, Heimbruch KE, Tarima S, Furumo Q, Brennan J, Zheng Y, Viny AD, Vassiliou GS, Rao S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35778533"},{"title01":"Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib","title02":"Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib","journal":"Leukemia","issue":"2022 Aug;36(8):2129-2131.","author":"Sigmund AM, Huang Y, Ruppert AS, Maddocks K, Rogers KA, Jaglowski S, Bhat SA, Kittai AS, Grever MR, Byrd JC, Woyach JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35842461"},{"title01":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","title02":"ASXL1<\/i> mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Jul 28. doi: 10.1038\/s41375-022-01648-4. Online ahead of print.","author":"Sch\u00f6nfeld L, Rinke J, Hinze A, Nagel SN, Sch\u00e4fer V, Schenk T, Fabisch C, Br\u00fcmmendorf TH, Burchert A, le Coutre P, Krause SW, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A, Ernst T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35902731"},{"title01":"Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL","title02":"Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL","journal":"Leukemia","issue":"Leukemia. 2022 Jul 28. doi: 10.1038\/s41375-022-01656-4. Online ahead of print.","author":"Cuthill KM, Zhang Y, Pepper A, Boelen L, Coulter E, Asquith B, Devereux S, Macallan DC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35902732"},{"title01":"Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants","title02":"Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants","journal":"Leukemia","issue":"Leukemia. 2022 Jul 28. doi: 10.1038\/s41375-022-01661-7. Online ahead of print.","author":"Escudero A, Takagi M, Auer F, Friedrich UA, Miyamoto S, Ogawa A, Imai K, Pascual B, Vela M, Stepensky P, Yasin L, Elitzur S, Borkhardt A, P\u00e9rez-Mart\u00ednez A, Hauer J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35902733"},{"title01":"Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia","title02":"Requirement for TP73<\/i> and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Jul 30. doi: 10.1038\/s41375-022-01655-5. Online ahead of print.","author":"Ong JZL, Yokomori R, Wong RWJ, Tan TK, Ueda R, Ishida T, Iida S, Sanda T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35908104"},{"title01":"Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia","title02":"Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Jul 30. doi: 10.1038\/s41375-022-01660-8. Online ahead of print.","author":"Soverini S, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Bruno S, Venturi C, Machova Polakova K, Ernst T, Maar D, Corner A, Cavo M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35908105"},{"title01":"Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia","title02":"Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Aug 1. doi: 10.1038\/s41375-022-01651-9. Online ahead of print.","author":"Feng P, Chen D, Wang X, Li Y, Li Z, Li B, Zhang Y, Li W, Zhang J, Ye J, Zhao B, Li J, Ji C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35915142"},{"title01":"Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603\/RATIFY trial","title02":"Genomic landscape of patients with FLT3<\/i>-mutated acute myeloid leukemia (AML) treated within the CALGB 10603\/RATIFY trial","journal":"Leukemia","issue":"Leukemia. 2022 Aug 3. doi: 10.1038\/s41375-022-01650-w. Online ahead of print.","author":"Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Ehninger G, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Thiede C, Stone RM, D\u00f6hner H, D\u00f6hner K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35922444"},{"title01":"Zanubrutinib joins the CLL treatment buffet","title02":"Zanubrutinib joins the CLL treatment buffet","journal":"Lancet Oncol","issue":"2022 Aug;23(8):965-967.","author":"Mozas P, Delgado J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35810752"},{"title01":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","title02":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1031-1043.","author":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, \u0160imkovi\u010d M, Shadman M, \u00d6sterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trn\u011bn\u00fd M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35810754"},{"title01":"Bendamustine in combination with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: A phase II trial","title02":"Bendamustine in combination with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: A phase II trial","journal":"Br J Haematol","issue":"2022 Jul;198(2):288-297.","author":"Kumar S, Sharma A, Malik PS, Gogia A, Pathak N, Sahoo RK, Gupta R, Prasad CP, Kumar L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35499209"},{"title01":"Plasma cell emperipolesis in multiple myeloma","title02":"Plasma cell emperipolesis in multiple myeloma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 19. doi: 10.1111\/bjh.18327. Online ahead of print.","author":"Bento LC, Nogueira BG, de Freitas Centuri\u00e3o N, Hamerschlak N, Souto EX, Bacal NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35852921"},{"title01":"Loss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma","title02":"Loss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma","journal":"Blood","issue":"Blood. 2022 Jul 19:blood.2022015909. doi: 10.1182\/blood.2022015909. Online ahead of print.","author":"Gooding S, Ansari-Pour N, Kazeroun MH, Karagoz K, Polonskaia A, Angulo Salazar M, Fitzsimons E, Sirinukunwattana K, Chavda SJ, Ortiz Estevez M, Towfic F, Flynt E, Pierceall W, Royston D, Yong KL, Ramasamy K, Vyas P, Thakurta A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35853156"},{"title01":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","title02":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","journal":"N Engl J Med","issue":"2022 Jul 14;387(2):132-147.","author":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35660812"},{"title01":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","title02":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1066-1077.","author":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839786"},{"title01":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","title02":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Jul 14:JCO2200491. doi: 10.1200\/JCO.22.00491. Online ahead of print.","author":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molu\u00e7on-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier AS, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35834762"},{"title01":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","title02":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Jul 14. doi: 10.3324\/haematol.2022.281242. Online ahead of print.","author":"Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35833303"},{"title01":"Upregulation of HIF-1\u03b1 contributes to complement activation in transplantation-associated thrombotic microangiopathy","title02":"Upregulation of HIF-1\u03b1 contributes to complement activation in transplantation-associated thrombotic microangiopathy","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 21. doi: 10.1111\/bjh.18377. Online ahead of print.","author":"Qi J, Pan T, You T, Tang Y, Chu T, Chen J, Fan Y, Hu S, Yang F, Ruan C, Wu D, Han Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35864790"},{"title01":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","title02":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","journal":"Br J Haematol","issue":"2022 Jul;198(2):278-287.","author":"D\u00e1vila J, Gonz\u00e1lez-Calle V, Escalante F, Cerd\u00e1 S, Puig N, Garc\u00eda-Sanz R, B\u00e1rez A, Montes C, L\u00f3pez R, Alonso JM, Aguilar C, Garc\u00eda-Mateo A, Labrador J, Aguilera C, Garc\u00eda-Coca A, Hern\u00e1ndez R, Mateos MV, Ocio EM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35383901"},{"title01":"The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis","title02":"The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis","journal":"Blood","issue":"Blood. 2022 Jul 25:blood.2022016194. doi: 10.1182\/blood.2022016194. Online ahead of print.","author":"Ghobadi A, Slade M, Kantarjian HM, Alvarenga J, Aldoss I, Mohammed K, Jabbour EJ, Faramand RG, Shah BD, Locke FL, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35877996"},{"title01":"Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","title02":"Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","journal":"Blood","issue":"Blood. 2022 Jul 19:blood.2022016082. doi: 10.1182\/blood.2022016082. Online ahead of print.","author":"Ho JG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Nunez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, R\u00fcckert T, M\u00e4rklin M, Holzmayer SJ, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, K\u00f6hler N, Duyster J, Menssen HD, Boerries M, Buescher J, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce E, Becher B, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35853161"},{"title01":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","title02":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1066-1077.","author":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839786"},{"title01":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","title02":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Jul 14:JCO2200491. doi: 10.1200\/JCO.22.00491. Online ahead of print.","author":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molu\u00e7on-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier AS, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35834762"},{"title01":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","title02":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","journal":"Br J Haematol","issue":"2022 Jul;198(2):278-287.","author":"D\u00e1vila J, Gonz\u00e1lez-Calle V, Escalante F, Cerd\u00e1 S, Puig N, Garc\u00eda-Sanz R, B\u00e1rez A, Montes C, L\u00f3pez R, Alonso JM, Aguilar C, Garc\u00eda-Mateo A, Labrador J, Aguilera C, Garc\u00eda-Coca A, Hern\u00e1ndez R, Mateos MV, Ocio EM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35383901"},{"title01":"Haematopoietic stem cell gene therapy in inborn errors of metabolism","title02":"Haematopoietic stem cell gene therapy in inborn errors of metabolism","journal":"Br J Haematol","issue":"2022 Jul;198(2):227-243.","author":"Chiesa R, Bernardo ME.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35535965"},{"title01":"Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness","title02":"Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness","journal":"Blood","issue":"Blood. 2022 Jul 26:blood.2022016112. doi: 10.1182\/blood.2022016112. Online ahead of print.","author":"Li C, Wu B, Li Y, Liu Y, Wang J, Xie J, Xu X, Tian X, Ye Z, Guan J, Chen J, Xie S, Zhang B, Cai B, Wang Q, Yu H, Lan T, Man CH, Kang X, Qian P, Perry JM, He A, Jiang L, Zhao M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35881840"},{"title01":"Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia","title02":"Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia","journal":"Leukemia","issue":"Leukemia. 2022 Jul 27. doi: 10.1038\/s41375-022-01636-8. Online ahead of print.","author":"Groarke EM, Patel BA, Shalhoub R, Gutierrez-Rodrigues F, Desai P, Leuva H, Zaimoku Y, Paton C, Spitofsky N, Lotter J, Rios O, Childs RW, Young DJ, Dulau-Florea A, Dunbar CE, Calvo KR, Wu CO, Young NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35896822"},{"title01":"The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH\/EHA Good Practice Paper","title02":"The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH\/EHA Good Practice Paper","journal":"Br J Haematol","issue":"2022 Aug;198(3):459-477.","author":"Roy NBA, Da Costa L, Russo R, Bianchi P, Ma\u00f1\u00fa-Pereira MDM, Fermo E, Andolfo I, Clark B, Proven M, Sanchez M, van Wijk R, van der Zwaag B, Layton M, Rees D, Iolascon A; British Society for Haematology\/ European Hematology Association.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35661144"},{"title01":"Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia","title02":"Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 25. doi: 10.1111\/bjh.18351. Online ahead of print.","author":"Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35876645"},{"title01":"Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells","title02":"Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells","journal":"Br J Haematol","issue":"2022 Jul;198(2):360-372.","author":"Taniguchi T, Nakayama S, Tanaka H, Rai S, Hirase C, Morita Y, Tatsumi Y, Ashida T, Matsuda M, Hashimoto S, Matsumura I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35451502"},{"title01":"Agranulocytosis in patients with Diamond-Blackfan anaemia (DBA) treated with deferiprone for post-transfusion iron overload: A retrospective study of the French DBA cohort","title02":"Agranulocytosis in patients with Diamond-Blackfan anaemia (DBA) treated with deferiprone for post-transfusion iron overload: A retrospective study of the French DBA cohort","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 19. doi: 10.1111\/bjh.18366. Online ahead of print.","author":"Lecornec N, Castex MP, R\u00e9guerre Y, Moreau P, Marie I, Gar\u00e7on L, Da Costa L, Leblanc T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35852515"},{"title01":"Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia","title02":"Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia","journal":"Blood","issue":"Blood. 2022 Jul 20:blood.2021015303. doi: 10.1182\/blood.2021015303. Online ahead of print.","author":"Niss O, Detterich JA, Wood JC, Coates TD, Malik P, Taylor M, Quinn CT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35857896"},{"title01":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","title02":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Jul 14:JCO2200491. doi: 10.1200\/JCO.22.00491. Online ahead of print.","author":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molu\u00e7on-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier AS, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35834762"},{"title01":"Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice","title02":"Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Jul 15:JCO2102707. doi: 10.1200\/JCO.21.02707. Online ahead of print.","author":"Amador C, Bouska A, Wright G, Weisenburger DD, Feldman AL, Greiner TC, Lone W, Heavican T, Smith L, Pileri S, Tabanelli V, Ott G, Rosenwald A, Savage KJ, Slack G, Kim WS, Hyeh Y, Li Y, Dong G, Song J, Ondrejka S, Cook JR, Barrionuevo C, Lim ST, Ong CK, Chapman J, Inghirami G, Raess PW, Bhagavathi S, Gould C, Blombery P, Jaffe E, Morris SW, Rimsza LM, Vose JM, Staudt L, Chan WC, Iqbal J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839444"},{"title01":"PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion","title02":"PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion","journal":"Haematologica","issue":"Haematologica. 2022 Jul 14. doi: 10.3324\/haematol.2022.280014. Online ahead of print.","author":"Taylor JG, Truelove E, Clear A, Calaminici M, Gribben JG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35833296"},{"title01":"Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001","title02":"Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001","journal":"Haematologica","issue":"Haematologica. 2022 Jul 14. doi: 10.3324\/haematol.2022.281004. Online ahead of print.","author":"Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35833300"},{"title01":"CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma","title02":"CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Jul 14. doi: 10.3324\/haematol.2022.281440. Online ahead of print.","author":"Gandhi MK, Keane C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35833302"},{"title01":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","title02":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Jul 14. doi: 10.3324\/haematol.2022.281242. Online ahead of print.","author":"Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35833303"},{"title01":"Bone health and glucocorticoid-containing lymphoma therapy – a review of risk factors and preventative measures","title02":"Bone health and glucocorticoid-containing lymphoma therapy – a review of risk factors and preventative measures","journal":"Br J Haematol","issue":"2022 Aug;198(3):431-442.","author":"Eyre TA, Jensen P, Booth S, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35235226"},{"title01":"A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial","title02":"A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial","journal":"Br J Haematol","issue":"2022 Aug;198(3):482-491.","author":"Hess G, H\u00fcttmann A, Witzens-Harig M, Dreyling MH, Keller U, Marks R, Ernst T, Pott C, Viardot A, Frontzek F, Trautmann M, Ruckes C, Deuster O, Rosenwald A, Theobald M, Lenz G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362552"},{"title01":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma – The UK real-world experience","title02":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma – The UK real-world experience","journal":"Br J Haematol","issue":"2022 Aug;198(3):492-502.","author":"Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O'Reilly M, Norman J, Osborne W, Bloor A, Lugthart S, Malladi R, Patten PEM, Neill L, Martinez-Cibrian N, Kennedy H, Phillips EH, Jones C, Sharplin K, El-Sharkawi D, Latif AL, Mathew A, Uttenthal B, Stewart O, Marzolini MAV, Townsend W, Cwynarski K, Ardeshna K, Ardavan A, Robinson K, Pagliuca A, Collins GP, Johnson R, McMillan A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35485402"},{"title01":"GOALs in relapsed DLBCL","title02":"GOALs in relapsed DLBCL","journal":"Br J Haematol","issue":"2022 Aug;198(3):419-420.","author":"R\u00f6sler W, Zenz T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35695285"},{"title01":"Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma","title02":"Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 21. doi: 10.1111\/bjh.18380. Online ahead of print.","author":"Rold\u00e1n Galiacho V, Zaldumbide Due\u00f1as L, Lobo Olmedo A, Alonso Varela M, Garc\u00eda-Ruiz JC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35861146"},{"title01":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","title02":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 21. doi: 10.1111\/bjh.18368. Online ahead of print.","author":"Strati P, Coleman M, Champion R, Ma S, Patti C, Levy MY, Lossos IS, Geethakumari PR, Lam S, Calvo R, Higgins K, Budde LE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35861370"},{"title01":"Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","title02":"Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 26. doi: 10.1111\/bjh.18376. Online ahead of print.","author":"Hartmann S, Soltani AS, Bankov K, Bein J, Hansmann ML, Rosenwald A, Bernd HW, Feller A, Ott G, M\u00f6ller P, Stein H, Klapper W, Borchmann P, Engert A, Eichenauer DA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35880396"},{"title01":"Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy","title02":"Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 27. doi: 10.1111\/bjh.18383. Online ahead of print.","author":"Weinstock M, Elavalakanar P, Bright S, Ambati SR, Brouwer-Visser J, Pourpe S, Fiaschi N, Jankovic V, Thurston G, Deering RP, Chaudhry A, Joyce R, Arnason J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35892294"},{"title01":"Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed\/refractory disease","title02":"Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol.<\/i> 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed\/refractory disease","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 27. doi: 10.1111\/bjh.18378. Online ahead of print.","author":"O'Reilly MA, Sanderson R, Wilson W, Iyengar S, Lambert J, McCulloch R, Eyre TA; BSH Guidelines Committee Haemato-oncology Task Force.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35894253"},{"title01":"Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1\u03b1 intersect to regulate angiogenesis in B-cell lymphoma","title02":"Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1\u03b1 intersect to regulate angiogenesis in B-cell lymphoma","journal":"Br J Haematol","issue":"2022 Jul;198(2):349-359.","author":"Ethiraj P, Sasi B, Holder KN, Lin AP, Qiu Z, Jaafar C, Elkhalili A, Desai P, Saksena A, Ritter JP, Aguiar RCT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35411936"},{"title01":"Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells","title02":"Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells","journal":"Br J Haematol","issue":"2022 Jul;198(2):360-372.","author":"Taniguchi T, Nakayama S, Tanaka H, Rai S, Hirase C, Morita Y, Tatsumi Y, Ashida T, Matsuda M, Hashimoto S, Matsumura I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35451502"},{"title01":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients","title02":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients","journal":"Br J Haematol","issue":"2022 Jul;198(2):267-277.","author":"Harrysson S, Eloranta S, Ekberg S, Enblad G, El-Galaly TC, Sander B, Sonnevi K, Andersson PO, Jerkeman M, Smedby KE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35468219"},{"title01":"End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma","title02":"End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma","journal":"Br J Haematol","issue":"2022 Jul;198(2):333-337.","author":"Dixon JG, Dimier N, Nielsen T, Zheng J, Marcus R, Morschhauser F, Evens AM, Federico M, Blum KA, Shi Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35491747"},{"title01":"Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma","title02":"Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma","journal":"Br J Haematol","issue":"2022 Jul;198(2):e32-e34.","author":"Dittus C, Miller JA, Wehbie R, Castillo JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35506301"},{"title01":"Outcomes of anti-programmed death 1 treatment for relapsed\/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis","title02":"Outcomes of anti-programmed death 1 treatment for relapsed\/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis","journal":"Br J Haematol","issue":"2022 Jul;198(2):401-404.","author":"Momotow J, B\u00fchnen I, Trautmann-Grill K, Kobbe G, Hahn D, Schroers R, Heinrich B, Gaska T, Forstbauer H, Schmidt B, Boger R, H\u00fcttmann A, Heil G, Kraemer DM, Kr\u00fcger W, Zeremski V, Grobe N, Jentsch-Ullrich K, Griesinger F, Fuchs M, von Tresckow B, Borchmann P, Engert A, Br\u00f6ckelmann PJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35538912"},{"title01":"B-cell lymphoma mimicking relapsing polychondritis","title02":"B-cell lymphoma mimicking relapsing polychondritis","journal":"Br J Haematol","issue":"2022 Jul;198(2):222.","author":"Dawudi Y, Benali K, Beydon M, Hourseau M, Sacre K, Papo T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35594183"},{"title01":"Bone marrow involvement by breast implant-associated anaplastic large cell lymphoma","title02":"Bone marrow involvement by breast implant-associated anaplastic large cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 14. doi: 10.1111\/bjh.18364. Online ahead of print.","author":"Du W, Estalilla OC, Jelic TM, Hayes JD, Tobin EC, Mei L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35834406"},{"title01":"Reed-Sternberg-like cells in a case of follicular lymphoma","title02":"Reed-Sternberg-like cells in a case of follicular lymphoma","journal":"Blood","issue":"2022 Jul 21;140(3):290.","author":"Ocampo Gonzalez FA, Ahmed A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35862091"},{"title01":"Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy","title02":"Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy","journal":"Blood","issue":"2022 Jul 14;140(2):152-156.","author":"Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, Fan X, Avila SV, Saharia KK, Husson JS, Niederhaus SV, Margiotta P, Lee ST, Law JY, Mannuel HD, Vander Mause E, Bauman S, Lesho P, Hankey K, Baddley J, Kocoglu M, Yared JA, Rapoport AP, Dahiya S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35537186"},{"title01":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","title02":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","journal":"Blood","issue":"Blood. 2022 Jul 15:blood.2022015478. doi: 10.1182\/blood.2022015478. Online ahead of print.","author":"Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie KA, Jaglowski SM, Radford J, Morschhauser F, Cunningham D, Martin Garcia-Sancho A, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, Cheng P, To C, Kersten MJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839452"},{"title01":"Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1","title02":"Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1","journal":"Blood","issue":"Blood. 2022 Jul 13:blood.2021014241. doi: 10.1182\/blood.2021014241. Online ahead of print.","author":"Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, Heid D, Renders S, G\u00f6llner S, Vierbaum L, Besenbeck B, Herbst SA, Knoll M, Kolb C, Przybylla A, Weidenauer K, Ludwig AK, Fabre MA, Gu M, Schlenk RF, St\u00f6lzel F, Bornh\u00e4user M, R\u00f6llig C, Platzbecker U, Baldus CD, Serve H, Sauer T, Raffel S, Pabst C, Vassiliou GS, Vick B, Jeremias I, Trumpp A, Krijgsveld J, M\u00fcller-Tidow C, Dietrich S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35857899"},{"title01":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","title02":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","journal":"N Engl J Med","issue":"2022 Jul 14;387(2):132-147.","author":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35660812"},{"title01":"Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?","title02":"Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?","journal":"Leukemia","issue":"Leukemia. 2022 Jul 25. doi: 10.1038\/s41375-022-01653-7. Online ahead of print.","author":"Seymour F, Carmichael J, Taylor C, Parrish C, Cook G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35879358"},{"title01":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","title02":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Jul 14:S2352-3026(22)00165-X. doi: 10.1016\/S2352-3026(22)00165-X. Online ahead of print.","author":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS; Non-communicable Disease Global Health Research Group, Association of Pacific Rim Universities.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35843248"},{"title01":"Improving the global reporting of multiple myeloma: a focus on low-income and middle-income countries","title02":"Improving the global reporting of multiple myeloma: a focus on low-income and middle-income countries","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Jul 14:S2352-3026(22)00213-7. doi: 10.1016\/S2352-3026(22)00213-7. Online ahead of print.","author":"Swaminathan R, Mehra N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35843249"},{"title01":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","title02":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","journal":"Haematologica","issue":"Haematologica. 2022 Jul 21. doi: 10.3324\/haematol.2022.280893. Online ahead of print.","author":"De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A, Offidani M, Petrucci MT, Ruggeri M, Santi RM, Barosi G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35861017"},{"title01":"Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma","title02":"Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma","journal":"Br J Haematol","issue":"2022 Aug;198(3):503-514.","author":"Cho H, Shin S, Chung H, Jang JE, Kim YR, Cheong JW, Min YH, Lee ST, Choi JR, Kim JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35505579"},{"title01":"Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma","title02":"Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma","journal":"Br J Haematol","issue":"2022 Aug;198(3):e38-e41.","author":"Kawano Y, Hata H, Takashio S, Tsujita K, Ueda M, Matsuoka M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35524546"},{"title01":"Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma","title02":"Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma","journal":"Br J Haematol","issue":"2022 Aug;198(3):515-522.","author":"B\u00f6ckle D, Tabares P, Zhou X, Schimanski S, Steinhardt MJ, Bittrich M, Seebacher E, Ulbrich M, Wilnit A, Metz C, Heidemeier A, Bley T, Werner R, Buck A, Einsele H, Kort\u00fcm KM, Beilhack A, Rasche L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35582835"},{"title01":"How I treat triple-class refractory multiple myeloma","title02":"How I treat triple-class refractory multiple myeloma","journal":"Br J Haematol","issue":"2022 Jul;198(2):244-256.","author":"Costa LJ, Hungria V, Mohty M, Mateos MV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35373352"},{"title01":"Multiple myeloma treatment – should be continued or not?","title02":"Multiple myeloma treatment – should be continued or not?","journal":"Br J Haematol","issue":"2022 Jul;198(2):223-224.","author":"Ozaki S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35468218"},{"title01":"Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia","title02":"Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"2022 Aug;198(3):414.","author":"AlHaj Issa Z, Altwijri A, Alfayez M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35499126"},{"title01":"Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia","title02":"Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia","journal":"Br J Haematol","issue":"2022 Aug;198(3):e35-e37.","author":"Jamy O, Lin K, Worth S, Bachiashvili K, Rangaraju S, Vachhani P, Bhatia R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35509246"},{"title01":"VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse","title02":"VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse","journal":"Br J Haematol","issue":"2022 Aug;198(3):523-527.","author":"Heraudet L, Galtier J, Favre S, Peyraud F, Cazaubiel T, Leroy H, Mottal N, Gros FX, Forcade E, Cl\u00e9ment L, Dumas PY, Pigneux A, Leguay T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35524489"},{"title01":"Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies","title02":"Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies","journal":"Br J Haematol","issue":"2022 Aug;198(3):478-481.","author":"Chan WY, Zhu C, Sanchez E, Gupta R, Fielding AK, Khwaja A, Payne EM, O'Nions J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35536283"},{"title01":"Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region","title02":"Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region","journal":"Br J Haematol","issue":"2022 Aug;198(3):413.","author":"Podvin B, Guermouche H, Fournier E, Berthon C, Duployez N, Roche-Lestienne C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35603637"},{"title01":"Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission","title02":"Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1<\/i> messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission","journal":"Br J Haematol","issue":"2022 Aug;198(3):600-603.","author":"Lu L, Kok CH, Dang P, Branford S, Saunders VA, Shanmuganathan N, Ross DM, Hughes TP, Yeung DTO.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35620965"},{"title01":"Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study","title02":"Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study","journal":"Br J Haematol","issue":"2022 Aug;198(3):545-555.","author":"S\u00e1nchez-Vizca\u00edno F, Tamayo C, Ramos F, L\u00e1inez-Gonz\u00e1lez D, Serrano-L\u00f3pez J, Barba R, Martin MD, Llamas P, Alonso-Dominguez JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35639095"},{"title01":"T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation","title02":"T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation","journal":"Br J Haematol","issue":"2022 Aug;198(3):556-573.","author":"Imbery JF, Heinzelbecker J, Jebsen JK, McGowan M, Myklebust C, Bottini N, Stanford SM, Sk\u00e5nland SS, Tveita A, Tj\u00f8nnfjord GE, Munthe LA, Szodoray P, Nakken B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35655388"},{"title01":"Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity","title02":"Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 22. doi: 10.1111\/bjh.18370. Online ahead of print.","author":"Copland M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35866251"},{"title01":"Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia","title02":"Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 25. doi: 10.1111\/bjh.18354. Online ahead of print.","author":"Li J, Liu L, Zhang R, Wan Y, Gong X, Zhang L, Yang W, Chen X, Zou Y, Chen Y, Guo Y, Ruan M, Zhu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35880261"},{"title01":"T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases","title02":"T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases","journal":"Br J Haematol","issue":"2022 Jul;198(2):e18-e22.","author":"Guo JJ, Cao L, Zhu HY, Miao Y, Du XY, Wu YJ, Wang L, Xu W, Li JY, Fan L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35396851"},{"title01":"Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia","title02":"Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia","journal":"Br J Haematol","issue":"2022 Jul;198(2):e23-e25.","author":"Shivarov V, Grigorova D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35415917"},{"title01":"Single-dose (4.5\u00a0mg\/m(2) ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia","title02":"Single-dose (4.5\u00a0mg\/m(2) ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia","journal":"Br J Haematol","issue":"2022 Jul;198(2):373-381.","author":"Dhunputh C, Strullu M, Petit A, Merched M, Pasquet M, Azarnoush S, Leverger G, Ducassou S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35438187"},{"title01":"Suppression of MYC by PI3K\/AKT\/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia","title02":"Suppression of MYC by PI3K\/AKT\/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia","journal":"Br J Haematol","issue":"2022 Jul;198(2):338-348.","author":"Stengel S, Petrie KR, Sbirkov Y, Stanko C, Ghazvini Zadegan F, Gil V, Skopek R, Kami\u0144ski P, Szyma\u0144ski \u0141, Brioli A, Zelent A, Schenk T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35468223"},{"title01":"Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall","title02":"Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall","journal":"Br J Haematol","issue":"2022 Jul;198(2):e28-e31.","author":"De Propris MS, Musiu P, Intoppa S, Nardacci MG, Pucciarini A, Santi A, Peragine N, Canichella M, De Luca ML, D'Elia GM, Del Giudice I, Pulsoni A, Falini B, Guarini A, Martelli M, Tiacci E, Fo\u00e0 R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35499213"},{"title01":"A new paradigm for the management of ATL","title02":"A new paradigm for the management of ATL","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 15. doi: 10.1111\/bjh.18363. Online ahead of print.","author":"Taylor GP, Cook LB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839073"},{"title01":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","title02":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 16. doi: 10.1111\/bjh.18357. Online ahead of print.","author":"Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35841338"},{"title01":"Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?","title02":"Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 19. doi: 10.1111\/bjh.18353. Online ahead of print.","author":"Moppett J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35852474"},{"title01":"Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark","title02":"Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 19. doi: 10.1111\/bjh.18350. Online ahead of print.","author":"Mogensen N, Saaranen E, Olsson E, Klug Albertsen B, L\u00e4hteenm\u00e4ki PM, Kreicbergs U, Heyman M, Harila-Saari A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35852790"},{"title01":"Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?","title02":"Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Jul 20. doi: 10.1111\/bjh.18372. Online ahead of print.","author":"van der Sluis IM, Bertrand Y, Baruchel A, Pieters R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35857756"},{"title01":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","title02":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","journal":"Blood","issue":"2022 Jul 21;140(3):285-289.","author":"Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Nov\u00e1k J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva L, Demeter J, Griffiths EA, Yee KWL, Issa JJ, Bewersdorf JP, Keer H, Hao Y, Azab M, D\u00f6hner H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35507690"},{"title01":"Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia","title02":"Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia","journal":"Blood","issue":"Blood. 2022 Jul 27:blood.2022016033. doi: 10.1182\/blood.2022016033. Online ahead of print.","author":"Kramer MH, Zhang Q, Sprung R, Day RB, Erdmann-Gilmore P, Li Y, Xu Z, Helton NM, George DR, Mi Y, Westervelt P, Payton JE, Ramakrishnan SM, Miller CA, Link DC, DiPersio JF, Walter MJ, Townsend RR, Ley TJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35895896"},{"title01":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","title02":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","journal":"Blood","issue":"2022 Jul 14;140(2):112-120.","author":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35427411"},{"title01":"Secondary AML with MLL gene amplification","title02":"Secondary AML with MLL<\/i> gene amplification","journal":"Blood","issue":"2022 Jul 14;140(2):161.","author":"Xu K, Nacheva E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35834280"},{"title01":"Ibrutinib frontline in young patients with CLL","title02":"Ibrutinib frontline in young patients with CLL","journal":"Blood","issue":"2022 Jul 14;140(2):80-81.","author":"Eichhorst B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35834283"},{"title01":"Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukaemia","title02":"Epigenetic regulator genes direct lineage switching in MLL\/AF4<\/i> leukaemia","journal":"Blood","issue":"Blood. 2022 Jul 15:blood.2021015036. doi: 10.1182\/blood.2021015036. Online ahead of print.","author":"Tirtakusuma R, Szoltysek K, Milne P, Grinev V, Ptasinska A, Chin PS, Meyer C, Nakjang S, Hehir-Kwa JY, Williamson D, Cauchy P, Keane P, Assi SA, Ashtiani M, Kellaway SG, Imperato MR, Vogiatzi F, Schweighart-James EK, Lin S, Wunderlich M, Stutterheim J, Komkov A, Zerkalenkova E, Evans P, McNeill HV, Elder A, Mart\u00ednez-Soria N, Fordham SE, Shi Y, Russell LJ, Pal D, Smith AG, Kingsbury Z, Becq J, Eckert C, Haas OA, Carey P, Bailey S, Skinner R, Miakova N, Collin M, Bigley V, Haniffa M, Marschalek R, Harrison CJ, Cargo CA, Schewe DM, Olshanskaya Y, Thirman MJ, Cockerill PN, Mulloy JC, Blair HJ, Vormoor HJ, Allan JM, Bonifer C, Heidenreich O, Bomken SN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839448"},{"title01":"Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","title02":"Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","journal":"Blood","issue":"Blood. 2022 Jul 19:blood.2022016082. doi: 10.1182\/blood.2022016082. Online ahead of print.","author":"Ho JG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Nunez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, R\u00fcckert T, M\u00e4rklin M, Holzmayer SJ, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, K\u00f6hler N, Duyster J, Menssen HD, Boerries M, Buescher J, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce E, Becher B, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35853161"},{"title01":"Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1","title02":"Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1","journal":"Blood","issue":"Blood. 2022 Jul 13:blood.2021014241. doi: 10.1182\/blood.2021014241. Online ahead of print.","author":"Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, Heid D, Renders S, G\u00f6llner S, Vierbaum L, Besenbeck B, Herbst SA, Knoll M, Kolb C, Przybylla A, Weidenauer K, Ludwig AK, Fabre MA, Gu M, Schlenk RF, St\u00f6lzel F, Bornh\u00e4user M, R\u00f6llig C, Platzbecker U, Baldus CD, Serve H, Sauer T, Raffel S, Pabst C, Vassiliou GS, Vick B, Jeremias I, Trumpp A, Krijgsveld J, M\u00fcller-Tidow C, Dietrich S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35857899"},{"title01":"APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations","title02":"APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53<\/i> mutations","journal":"Leukemia","issue":"Leukemia. 2022 Jul 14. doi: 10.1038\/s41375-022-01634-w. Online ahead of print.","author":"Hong Y, Ren T, Wang X, Liu X, Fei Y, Meng S, Han X, Sun C, Shen H, Li L, Qiu L, Qian Z, Zhou S, Zhang H, Wang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35835991"},{"title01":"PARP14 is a novel target in STAT6 mutant follicular lymphoma","title02":"PARP14 is a novel target in STAT6<\/i> mutant follicular lymphoma","journal":"Leukemia","issue":"Leukemia. 2022 Jul 18. doi: 10.1038\/s41375-022-01641-x. Online ahead of print.","author":"Mentz M, Keay W, Strobl CD, Antoniolli M, Adolph L, Heide M, Lechner A, Haebe S, Osterode E, Kridel R, Ziegenhain C, Wange LE, Hildebrand JA, Shree T, Silkenstedt E, Staiger AM, Ott G, Horn H, Szczepanowski M, Richter J, Levy R, Rosenwald A, Enard W, Zimber-Strobl U, von Bergwelt-Baildon M, Hiddemann W, Klapper W, Schmidt-Supprian M, Rudelius M, Bararia D, Passerini V, Weigert O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35851155"},{"title01":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","title02":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","journal":"Lancet Oncol","issue":"2022 Aug;23(8):1066-1077.","author":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35839786"},{"title01":"Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial","title02":"Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Jul 22:JCO2101281. doi: 10.1200\/JCO.21.01281. Online ahead of print.","author":"Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, Andr\u00e9 M; LYSA-FIL-EORTC Intergroup.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35867960"},{"title01":"Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index","title02":"Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index","journal":"J Clin Oncol","issue":"2022 Jul 20;40(21):2352-2360.","author":"Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, D\u00fchrsen U, Ceriani L, Schmitz C, Wiegers SE, H\u00fcttmann A, Lugtenburg PJ, Zucca E, Zwezerijnen GJC, Hoekstra OS, Zijlstra JM, Barrington SF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357901"},{"title01":"Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome","title02":"Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome","journal":"Leukemia","issue":"Leukemia. 2022 Jul 22. doi: 10.1038\/s41375-022-01657-3. Online ahead of print.","author":"Janssen JJWM, L\u00f6wenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, St\u00fcssi G, van Norden Y, Ossenkoppele GJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35869267"},{"title01":"Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib","title02":"Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib","journal":"Leukemia","issue":"Leukemia. 2022 Jul 16. doi: 10.1038\/s41375-022-01640-y. Online ahead of print.","author":"Sigmund AM, Huang Y, Ruppert AS, Maddocks K, Rogers KA, Jaglowski S, Bhat SA, Kittai AS, Grever MR, Byrd JC, Woyach JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35842461"},{"title01":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","title02":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Jul 18. doi: 10.1038\/s41375-022-01647-5. Online ahead of print.","author":"R\u00f6hnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause SW, B\u00fccklein V, Hoffmann J, Jaramillo S, Schlenk RF, R\u00f6llig C, Bornh\u00e4user M, McCarthy N, Freeman S, Oelschl\u00e4gel U, von Bonin M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35851154"},{"title01":"Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children’s Oncology Group","title02":"Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children’s Oncology Group","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Jul 20:S2352-3026(22)00168-5. doi: 10.1016\/S2352-3026(22)00168-5. Online ahead of print.","author":"Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, Castellino SM, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35870472"},{"title01":"Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","title02":"Venetoclax Plus Gilteritinib for FLT3<\/i>-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Jul 18:JCO2200602. doi: 10.1200\/JCO.22.00602. Online ahead of print.","author":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35849791"},{"title01":"Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens","title02":"Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens","journal":"Haematologica","issue":"Haematologica. 2022 Jul 21. doi: 10.3324\/haematol.2022.280728. Online ahead of print.","author":"Jensen CE, Heiling HM, Beke KE, Deal AM, Bryant AL, Coombs LA, Foster MC, Richardson DR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35861016"},{"title01":"Low-intensity induction in acute myeloid leukemia. Always in the patients’ best interest?","title02":"Low-intensity induction in acute myeloid leukemia. Always in the patients’ best interest?","journal":"Haematologica","issue":"Haematologica. 2022 Jul 21. doi: 10.3324\/haematol.2022.281506. Online ahead of print.","author":"Atallah E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35861019"},{"title01":"RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia","title02":"RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Jul 14. doi: 10.3324\/haematol.2022.280757. Online ahead of print.","author":"Zhang H, Cai B, Liu Y, Chong Y, Matsunaga A, Mori SF, Fang X, Kitamura E, Chang CS, Wang P, Cowell JK, Hu T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35833297"},{"title01":"Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data","title02":"Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data","journal":"Haematologica","issue":"Haematologica. 2022 Jul 14. doi: 10.3324\/haematol.2022.280765. Online ahead of print.","author":"Othus M, Garcia-Manero G, Godwin JE, Weick JK, Appelbaum FR, Erba HP, Estey EH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35833298"},{"title01":"Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia","title02":"Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2022 Aug;198(3):421-430.","author":"Valtis YK, Place AE, Silverman LB, Vrooman LM, DeAngelo DJ, Luskin MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35312041"},{"title01":"A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial","title02":"A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial","journal":"Br J Haematol","issue":"2022 Aug;198(3):528-534.","author":"Russell NH, Hills RK, Kjeldsen L, Clark RE, Ali S, Cahalin P, Thomas IF, Burnett AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35388465"},{"title01":"A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM’s “pick a winner” trial, with the impact of somatic mutations","title02":"A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM’s “pick a winner” trial, with the impact of somatic mutations","journal":"Br J Haematol","issue":"2022 Aug;198(3):535-544.","author":"Ad\u00e8s L, Duployez N, Guerci-Bresler A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Dimicoli-Salazar S, Braun T, Beyne-Rauzy O, Marolleau JP, Cheze S, Park S, Cluzeau T, Nimubona S, Bordessoule D, Benramdane R, Quesnel B, Am\u00e9 S, de Botton S, Chermat F, Preudhomme C, Chevret S, Fenaux P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35438802"}]